Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

October 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

SENSASURE TECHNOLOGIES INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada

001-41209

87-2406468

(State or other jurisdiction
of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

4730 S. Fort Apache Rd., Suite 300

Las Vegas, NV

89147

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (347) 325-4677

N/A

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		SSTC		OTC QB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of December 15, 2023, 56,349,183 shares of common stock, $0.01 par value per share, were issued and outstanding.

SENSASURE TECHNOLOGIES, INC.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(In U.S. Dollars, except share data or otherwise stated)

FOR THE THREE AND SIX MONTHS PERIOD

OCTOBER 31, 2023 AND 2022

INDEX TO FINANCIAL STATEMENTS

Condensed Interim Consolidated Financial Statements for the three and six months ended October 31, 2023 and 2022:
Condensed Interim Consolidated Balance Sheets at October 31, 2023 (unaudited) and April 30, 2023 (audited)	F-2
Condensed Interim Consolidated Statements of Loss for the three and six months ended October 31, 2023 and 2022 (unaudited)	F-3
Condensed Interim Consolidated Statements of Comprehensive Loss for the three and six months ended October 31, 2023 and 2022 (unaudited)	F-4
Condensed Interim Consolidated Statements of Stockholders’ Deficiency for the three and six months ended October 31, 2023 and 2022 (unaudited)	F-5
Condensed Interim Consolidated Statements of Cash Flows for the six months ended October 31, 2023 and 2022 (unaudited)	F-6
Notes to Condensed Interim Consolidated Financial Statements	F-7

F-1

SENSASURE TECHNOLOGIES, INC.

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(In U.S. Dollars, except share data or otherwise stated)

as of October 31, 2023 and April 30, 2023

	Note	As at October 31, 2023 (unaudited)			As at April 30, 2023 (audited)
		$			$
ASSETS
Current assets:
Cash	3(b)		3,135			26,786
Restricted cash held in trust	3(b)		-			172
Accounts receivable			788			-
Subscription receivable	4,8(b)		-			-
Prepayments and other receivables			11,435			12,688
Total current assets			15,358			39,646
Total assets			15,358			39,646

LIABILITIES AND STOCKHOLDERS’ DEFIECIENCY
Current liabilities:
Accounts payable and accrued liabilities	5		109,579			105,868
Accounts payable and accrued liabilities to a related party	7(c)		470,445			486,826
Demand Loans	6		137,694			113,375
Loans from related parties	7(b)		76,074			82,823
Amount due to related parties	7(a)		371,736			312,347
Total current liabilities			1,165,528			1,101,239

Total liabilities			1,165,528			1,101,239

STOCKHOLDERS’ DEFICIECY
Class A Preferred stock, $0.001 par value, 5,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding shares: Nil and Nil as at October 31, 2023 and April 30, 2023, respectively.	8		-			-
Class B Preferred stock, $0.001 par value, 5,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding shares: Nil and Nil as at October 31, 2023 and April 30, 2023, respectively.	8		-			-
Common stock, $0.01 par value, 250,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding common shares: and 56,349,183 as at October 31, 2023 and 56,349,183 at April 30, 2023, respectively.	8		447,431			425,431
Shares to be issued (804,000 and 804,000 common shares at October, 2023 and April 30, 2023 respectively)	8		15,755			15,755
Additional paid-in capital			4,665,073			4,533,073
Foreign currency translation reserve			(170,131	)		(231,505	)
Accumulated deficit			(6,334,768	)		(6,027,209	)
Total deficit attributable to equity holders of the Company			(1,376,640	)		(1,284,455	)
Total equity attributable to non-controlling interests			45,669			42,061
Development reserve	8(d)		180,801			180,801
Total deficit			(1,150,170	)		(1,061,593	)
Total liabilities and stockholders’ deficiency			15,358			39,646

Reverse Recapitalization (Note 1)

Contingencies (Note 9)

Subsequent events (Note 10)

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

F-2

SENSASURE TECHNOLOGIES, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(In U.S. Dollars, except share data or otherwise stated)

	Note	Three Months Ended October 31, 2023 (unaudited)			Three Months Ended October 31, 2022 (unaudited)			Six Months Ended October 31, 2023 (unaudited)			Six Months Ended October 31, 2022 (unaudited)
		$			$			$			$

Revenue	3(a)		811			680			1,146			4,414

Expenses
General and administrative expense	8(b)		(154,467	)		(132,641	)		(296,352	)		(313,909	)
Research and development expense	3(f),7		(3,231	)		(19,421	)		(10,145	)		(19,421	)
TOTAL OPERATING EXPENSES			(157,698	)		(152,062	)		(306,497	)		(333,330	)

Interest expenses, net	6,7		(1,968	)		(1,995	)		(4,009	)		(4,132	)
Other income (expenses), net
NET LOSS BEFORE INCOME TAXES			(158,855	)		(153,377	)		(309,360	)		(333,048	)
Income taxes
NET LOSS			(158,855	)		(153,377	)		(309,360	)		(333,048	)
Less: net loss attributable to non-controlling interests			164			4,277			1,801			5,797
Net loss attributable to the Company			(158,691	)		(149,100	)		(307,559	)		(327,251	)

Basic and diluted loss per share			(0.003	)		(0.001	)		(0.005	)		(0.003	)

Weighted average number of common shares outstanding			56,349,183			105,723,183			56,349,183			105,723,183

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

See effect of reverse recapitalization (Note 1)

F-3

SENSASURE TECHNOLOGIES, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(In U.S. Dollars, except share data or otherwise stated)

	Three Months Ended October 31, 2023 (unaudited)			Three Months Ended October 31, 2022 (unaudited)			Six Months Ended October 31, 2023 (unaudited)			Six Months Ended October 31, 2022 (unaudited)
	$			$			$			$

Net loss for the period		(158,855	)		(153,377	)		(309,360	)		(333,048	)
Foreign currency translation adjustments		48,585			61,005			66,783			73,357
Total comprehensive loss for the period		(110,270	)		(92,372	)		(242,577	)		(259,691	)

Attributable to:
Net loss attributable to the Company		(158,691	)		(149,100	)		(307,559	)		(327,251	)
Foreign currency translation adjustments attributable to the Company		44,353			57,058			61,374			68,612
Net loss attributable to non-controlling interests		(164	)		(4,277	)		(1,801	)		(5,797	)
Foreign currency translation adjustments attributable to non-controlling interests		4,232			3,947			5,409			4,745
		(110,270	)		(92,372	)		(242,577	)		(259,691	)

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

See effect of reverse recapitalization (Note 1)

F-4

SENSASURE TECHNOLOGIES, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

(In U.S. Dollars, except share data or otherwise stated)

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Foreign Currency Translation Reserve			Accumulated deficit			(Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		$		Shares		$		Shares		$		Shares		$		$		$			$			$			$			$		$
Balance at July 31, 2023 (unaudited)				56,349,183		436,431		-		-		-		-		804,000		15,755		4,599,073		(214,484	)		(6,176,077	)		(1,339,302	)		41,601			180,801		(1,116,900	)
Amortization of vested shares		8		-		11,000		-		-		-		-		-		-		66,000		-			-			77,000			-			-		77,000
Loss for the period				-		-		-		-		-		-		-		-		-		-			(158,691	)		(158,691	)		(164	)		-		(158,855	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		44,353			-			44,353			4,232			-		48,585
Balance at October 31, 2023 (unaudited)				56,349,183		447,431		-		-		-		-		804,000		15,755		4,665,073		(170,131	)		(6,334,768	)		(1,376,640	)		45,669			180,801		(1,150,170	)

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Accumulated Other Comprehensive Loss			Accumulated deficit			(Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		US$		Shares		US$		Shares		US$		Shares		US$		US$		US$			US$			US$			US$			US$		US$
Balance at July 31, 2022 (unaudited)				105,723,183		615,731		-		-		-		-		-		-		4,205,409		(235,688	)		(5,495,271	)		(909,819	)		53,275			240,641		(615,903	)
Amortization of vested shares		8		-		6,380		-		-		-		-		-		-		8,196		-			-			14,576			-			-		14,576
Issuance of common shares for service		8		-		-		-		-		-		-		36,000		2,520		-		-			-			2,520			-			-		2,520
Loss for the period				-		-		-		-		-		-		-		-		-		-			(149,100	)		(149,100	)		(4,277	)		-		(153,377	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		57,058			-			57,058			3,947			-		61,005
Balance at October 31, 2022 (unaudited)				105,723,183		622,111		-		-		-		-		36,000		2,520		4,213,605		(178,630	)		(5,644,371	)		(984,765	)		52,945			240,641		(691,179	)

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Foreign Currency Translation Reserve			Accumulated deficit			(Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		$		Shares		$		Shares		$		Shares		$		$		$			$			$			$			$		$
Balance at April 30, 2023 (audited)				56,349,183		425,431		-		-		-		-		804,000		15,755		4,533,073		(231,505	)		(6,027,209	)		(1,284,455	)		42,061			180,801		(1,061,593	)
Amortization of vested shares		8		-		22,000		-		-		-		-		-		-		132,000		-			-			154,000			-			-		154,000
Loss for the period				-		-		-		-		-		-		-		-		-		-			(307,559	)		(307,559	)		(1,801	)		-		(309,360	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		61,374			-			61,374			5,409			-		66,783
Balance at October 31, 2023 (unaudited)				56,349,183		447,431		-		-		-		-		804,000		15,755		4,665,073		(170,131	)		(6,334,768	)		(1,376,640	)		45,669			180,801		(1,150,170	)

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Accumulated Other Comprehensive Loss			Accumulated deficit			Equity (Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		US$		Shares		US$		Shares		US$		Shares		US$		US$		US$			US$			US$			US$			US$		US$
Balance at April 30, 2022 (audited)				105,723,183		609,351		-		-		-		-		-		-		4,197,213		(195,610	)		(4,433,352	)		177,602			(881,448	)		240,641		(463,205	)
Subsidiary issuance of shares pursuant to private placement		8		-		-		-		-		-		-		-		-		-		-			-			-			45			-		45
Amortization of vested shares		8		-		12,760		-		-		-		-		-		-		16,392		-			-			29,152			-			-		29,152
Issuance of common shares for service		8		-		-		-		-		-		-		36,000		2,520		-		-			-			2,520.00			-			-		2,520
Loss for the period				-		-		-		-		-		-		-		-		-		-			(327,251	)		(327,251	)		(5,797	)		-		(333,048	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		68,612			-			68,612			4,745			-		73,357
Effect of dilution of ownership in subsidiary pursuant to issuance of shares		8		-		-		-		-		-		-		-		-		-		(51,632	)		(883,768	)		(935,400	)		935,400			-		-
Balance at October 31, 2022 (unaudited)				105,723,183		622,111		-		-		-		-		36,000		2,520		4,213,605		(178,630	)		(5,644,371	)		(984,765	)		52,945			240,641		(691,179	)

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

See effect of reverse recapitalization (Note 1)

F-5

SENSASURE TECHNOLOGIES, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(In U.S. Dollars, except share data or otherwise stated)

		Six Months			Six Months
		Ended			Ended
		October 31,			October 31,
		2023			2022
	Note	(unaudited)			(unaudited)
		$			$
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(309,360)			(333,048)
Adjustments for:
Amortization of vested shares	8(b)		154,000			29,152
Issuance of shares for services	8(b)		-			2,520
Changes in:
Accounts receivable			(788	)		(2,089	)
Prepayments and other receivables			1,253			(1,750	)
Accounts payable and accrued liabilities to third parties and a related party			(12,670	)		(43,363	)
Amounts due to related parties			59,389			51,544
Long term payable to a related party			-			(17,935	)
Net cash used in operating activities			(108,176	)		(314,969	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from subsidiary issuance of shares to noncontrolling interests			-			45
Proceeds from related party loans			70,279			-
Net cash provided by financing activities			70,279			45

Effect of exchange rate changes on cash and restricted cash held in trust			14,074			26,387
Net decrease in cash and restricted cash held in trust			(23,823	)		(288,537	)
Cash and restricted cash held in trust at the beginning of period			26,958			437,177
Cash and restricted cash held in trust at the end of period			3,135			148,640

Supplemental cash flows information
Income tax paid			-			-
Interest paid			-			-

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

See effect of reverse recapitalization (Note 1)

F-6

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

1.	DESCRIPTION OF BUSINESS

SensaSure Technologies, Inc. (“SensaSure” or “Company”) was incorporated on September 8, 2020 under the laws of the State of Nevada with an authorized share capital of 250,000,000 common shares, 5,000,000 of Class A and 5,000,000 Class B preferred shares. The Company did not issue any number of common shares, Class A and Class B preferred shares before December 21, 2020.

Sensa Bues AB (“Sensa Bues”) was incorporated in the Kingdom of Sweden in November 2009. Sensa Bues AB owns the core intellectual properties for the design of sample collection devices and the methodologies to collect, extract and detect the non-volatile substances presented within aerosols in exhaled breath. These aerosols, which originate from the lungs and blood, are captured using electret-based filter technologies. This non-invasive breath-based biological sample collection and testing methodology is called ExaBreath (“EB”) technology.

Sensa Bues AB performs medical device design and research focusing on developing and commercializing EB for disease detection, exposure monitoring, and drug metabolism.

During April 2021, the Company increased its ownership interest in Sensa Bues AB pursuant to private placements completed by Sensa Bues AB where 277,296 common shares and 93,032 common shares were issued to the Company and noncontrolling interests respectively. (Note 8 (b)).

During the six months ended October 31, 2022, the Company increased its ownership interest in Sensa Bues AB pursuant to private placements completed by Sensa Bues where 2,200,000 common shares and 440 common shares were issued to the Company and noncontrolling interests respectively. (Note 8 (b)).

On October 31, 2023, the Company owned 93.53% (93.53% - April 30, 2023) of the total issued and outstanding common shares in Sensa Bues. On October 31, 2022, the Company owned 93.53% (74% - April 30, 2022) of the total issued and outstanding common shares in Sensa Bues AB (Note 8 (c)).

2.	BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

(a)	Basis of Presentation

The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with the Company’s audited consolidated financial statements for the years ended April 30, 2023 and 2022 and their accompanying notes.

The accompanying unaudited condensed interim consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending April 30, 2024. The Company’s fiscal year-end is April 30.

The unaudited condensed interim consolidated financial statements include the accounts of the Company and its less than wholly owned subsidiary, Sensa Bues AB. Intercompany accounts and transactions have been eliminated.

Certain prior quarter amounts have been reclassified for consistency with the current period presentation. These reclassifications has no effect on the reported results of the operations or cash flows.

F-7

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

(b)	Basis of Consolidation

Sensa Bues AB and SensaSure were deemed to be under common control. Accordingly, the combination of the two entities has been accounted for as a reorganization of entities under common control in accordance with ASC 805 guidelines, whereby the resulting controlling entity, namely, SensaSure recognized the assets and liabilities of the Sensa Bues AB transferred at their carrying amounts with a carry-over basis. The reorganization of entities under common control was retrospectively applied to the financial statements of all prior periods when the financial statements are issued for a period that includes the date the share exchange transaction occurred.

Equity interests in Sensa Bues AB held by parties other than SensaSure are presented as non-controlling interests in equity.

(c)	Liquidity and going concern

The Company is in the early stages of commercializing its product and in the process of its initial public offering. It is concurrently in development mode, operating research and development programs in order to develop an ecosystem of technologies and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at October 31, 2023 and April 30, 2023, had an accumulated deficit of $6,334,768 and $6,027,209 respectively, a working capital deficiency of $1,150,170 and $1,061,593 respectively. The Company, during year ended April 30, 2022 and April 30, 2021, through several private placements, raised $368,200 and $893,014 respectively (Note 8 (b)). The Company, during year ended April 30, 2023, obtained working capital loans from related parties in the amount of $39,979. On March 30, 2021, Sensa Bues AB, through an agreement with a vendor that is controlled by a then-director of Sensa Bues AB, modified the payment term of payable balance in the amount of $333,744 to settle the payable balance in seven installments, the payable balance became current on April 30, 2023 (Note 7 (c)).

The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove to be accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the absence of additional appropriate financing, the Company may have to modify its operating plan or slow down the pace of development and commercialization of its proposed products.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on the Company’s ability to meet obligations as they become due and to obtain additional equity or alternative financing required to fund operations until sufficient sources of recurring revenues can be generated.

These unaudited condensed interim consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company expects to finance their future operations primarily through cash flow from capital contributions from the shareholders of the Company. In the event that the Company requires additional funding to finance the growth of the Company’s current and expected future operations as well as to achieve our strategic objectives, the shareholders of the Company indicated the intent and ability to provide additional equity financing.

In December 2019, a novel strain of coronavirus (COVID-19) emerged. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it had spread to several other countries and infections have been reported globally.

During the past several years, as a result of COVID-19 infections having been reported throughout both the United States and Sweden, certain national, provincial, state and local governmental issued proclamations and/or directives aimed at minimizing the spread of COVID-19. Due to the disruption of the COVID-19 crisis, the Company’s business activities might be subject to certain level of adverse impact. At the date of approval of these unaudited condensed interim consolidated financial statements, it is still not possible to reliably estimate the effect of these developments as well as the impact on the financial results and condition of the Company in future periods. Management is monitoring these developments on the Company’s operations and is taking all steps to ensure that employees are following all public health and safety protocols.

F-8

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a)	Revenue recognition

The Company sells devices with collection mechanism for biological samples based upon exhaled breath. Revenue comprises devices delivered to the Company’s customers.

In accordance with ASC 606 - Revenue from Contracts with Customers, the Company recognizes revenue upon the transfer of goods to a customer at an amount that reflects the expected consideration to be received in exchange for those goods. The Company accounts for a customer contract when the rights of the parties, including the payment terms, are identified, the contract has commercial substance, collection of consideration is probable, and the contract has been signed and agreed to by both parties. Revenue is recognized when performance obligations are satisfied by transferring control or economic benefit of the goods to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for its goods.

The principles in ASC 606 are applied using the following five steps:

Identify the contract with a customer;

Identify the performance obligation(s) in the contract;

Determine the transaction price;

Allocate the transaction price to the performance obligation(s) in the contract; and

Recognize revenue when (or as) the performance obligation(s) are satisfied.

(b)	Cash and restricted cash held in trust

Cash includes cash on hand and balances with banks. Restricted cash includes proceeds from private placements and shareholder loans financing completed by the Company during years ended April 30, 2021, 2022, 2023 and quarter ended October 31, 2023 that are held in an escrow account. As per the share subscription agreements from January to April 2021, and the Escrow Agreement dated January 26, 2021, restricted cash can only be used for expenses related to listing process and for professional expenses of the first eighteen months’ statutory filings from the date the Company successfully completes the listing process.

(c)	Non-controlling interests

The non-controlling interests represent the portion of the equity (net assets) in the subsidiary not directly or indirectly attributable to the Company. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets, statements of loss, statements of comprehensive loss and statements of stockholders’ deficiency attributed to controlling and non-controlling interests.

(d)	Critical management judgment and use of estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals, stock options, principles of consolidation and reverse recapitalization and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

(e)	Accounts receivable

Accounts receivable consists of amounts due to the Company from research institutions. Accounts receivable is reported on the balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

(f)	Research and development

Research and development and all patent maintenance and related filing costs are charged to operations as incurred as the Company is uncertain as to any future economic benefit.

F-9

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

(g)	Stock based compensation

The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire and compensate for goods or services received, including grants of employee shares, be recognized in the statement of loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period.

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable. The Company issues compensatory shares for services including, but not limited to, executive, management, operations, corporate communication, finance and administrative consulting services.

(h)	Foreign Currency Translation

The functional currency of the Company’s Swedish-based subsidiary is the Swedish Krona (“SEK”) and the US-based parent is the U.S. dollar (“USD”). Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net loss for the reporting period. In translating the financial statements of the Company’s Swedish subsidiary from their functional currency into the Company’s reporting currency of USD, balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in equity. The Company has not, to the date of These unaudited condensed interim consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

(i)	Fair Value of financial instruments

The Company’s financial instruments consist primarily of cash and restricted cash held in trust, accounts receivable, subscription receivable, other receivables, accounts payable and accrued liabilities, demand loans, loans from related parties, amounts due to related parties. The carrying amounts of these balances approximate their fair values due to the short-term maturities of these instruments. The carrying value of long term payable to a related party approximates its fair values due to current market rate on such debt.

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

●

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

●

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

●

Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

F-10

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash and restricted cash held in trust, accounts receivable, subscription receivable, other receivables, accounts payable and accrued liabilities, demand loans, loans from related parties, amounts due to related parties and long term payable to a related party. The Company’s cash and restricted cash held in trust, which are carried at fair values, are classified as Level 1. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

(j)	Income Taxes

Income taxes are computed under the asset and liability method reflecting both current and deferred taxes, which reflect the tax impact of all events included in the consolidated financial statements. The balance sheet approach (i) reflects a current tax liability or asset recognized for estimated taxes payable or refundable on tax returns for the current and prior years, (ii) reflects a deferred tax liability or asset recognized for the estimated future tax effects attributable to temporary differences and carry forwards, (iii) measures current and deferred tax liabilities and assets using the enacted tax rate of which the effects of future changes in tax laws or rates are not anticipated, and (iv) reduces deferred tax assets, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company recognizes deferred tax assets only to the extent that management concludes these assets are more-likely-than-not to be realized. Significant judgement is required in assessing and estimating the more-likely-than-not tax consequences of the events included in the consolidated financial statements. Management considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (i) management determines whether it is more likely- than-not that the tax position will be sustained on the technical merits of the position and (ii) for those tax positions that meet the more likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

(k)	Loss per share

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at October 31, 2023, April 30, 2023 and October 31, 2022.

(l)	Operating Segments

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. All revenues are currently earned in Sweden and significantly all of the assets of the Company are used for the Company’s medical device design and research and distribution activities that is carried out in Sweden. The Company has one reportable segment and operating segment: Medical device design and research and distribution.

F-11

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

(m)	Recently issued accounting pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company does not expect that this guidance will have a significant impact on the Company’s consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows.

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows.

The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

4.	SUBSCRIPTION RECEIVABLE

During the year ended April 30, 2021, SensaSure, via several private placements with proceeds of $793,000 for 12,200,000 common shares subscribed, issued 11,780,000 common shares. The proceeds received was reflected as an increase in common stock in amount of $117,800 and additional paid-in capital in amount of $647,900 respectively. The Company recognized a subscription receivable and shares to be issued in amount of $27,300 at April 30, 2021. The number of shares to be issued was 420,000. During the year ended April 30, 2022, the Company received the subscription proceeds and issued 420,000 common shares accordingly (Note 8 (b)).

5.	ACCOUNTS PAYABLE AND ACCRUED LIABILITIES TO THIRD PARTIES

	As of
	October 31, 2023		April 30, 2023
Accounts payable	$	46,079	$	53,868
Accrued liabilities		63,500		52,000
	$	109,579	$	105,868

6.	DEMAND LOANS

At October 31, 2023 and April 30, 2023, the Company had balances in unsecured demand loans from several noncontrolling interests in Sensa Bues AB and a shareholder totaling $26,223 (SEK 293,000) and $28,550 (SEK 293,000), respectively. The loans had an interest rate of 20% per annum. For the six months ended October 31, 2023 and 2022, interest expense was $2,719 and $2,802, respectively.

At October 31, 2023 and April 30, 2023, the Company had balances in unsecured demand loans from a party who has a noncontrolling interests in Sensa Bues AB of $41,192 (SEK 460,247) and $44,846 (SEK 460,247), respectively. The loans had an interest rate of 2% per annum. For the six months ended October 31, 2023 and 2022 , interest expense was $427 and $440, respectively.

At October 31, 2023, the Company had balance in demand loan in the amount of $70,279 from several shareholders (April 30, 2023 - $39,979). Those loans are unsecured, non-interest bearing and due on demand.

F-12

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

7.	RELATED PARTIES TRANSACTIONS

The Company had the following balances and transaction with related parties except disclosed in other notes.:

(a)	Amounts due to related parties

At October 31, 2023 and April 30, 2023, salary payable to the former CEO of the Company who is also a director of Sensa Bues AB included in amounts due to related parties was $371,736 and $312,347, respectively.

On March 31, 2021, the Company, Sensa Bues AB and the former CEO of the Company who is also a director of Sensa Bues AB reached an agreement to settle account payable in the amount of $326,337 by issuing options to purchase common shares of Sensa Bues AB with a guarantee of subscription of the Company’s common shares upon exercise of the option by the optionee (Note 2 (c) and Note 8 (b)). The agreement allows the director to subscribe aggregated 3,400 common shares of Sensa Bues AB. The term of the Agreement is for thirty-six months from March 31, 2021. The Company guaranteed that it shall purchase shares of the optionee during the term of the agreement based on the formula of 50 common shares of the Company for each one shares the optionee subscribed of Sensa Bues AB.

At October 31, 2023 and April 30, 2023, expenses paid on behalf of the Company by two former directors of Sensa Bues AB included in amounts due to related parties was $nil and $ nil, respectively.

At October 31, 2023 and April 30, 2023, amounts payable to a former director of Sensa Bues AB included in amounts due to related parties was $nil and $ nil, respectively.

(b)	Loans from related parties

At October 31, 2023 and April 30, 2023, balances of loan from a former director of SensaSure were $49,224 (SEK550,000) and $53,591 (SEK550,000), respectively. The loan is unsecured, bearing interest at 2% per annum and due on demand. The interest expense was $510 and $568 for six months ended October 31, 2023 and 2022, respectively.

At October 31, 2023 and April 30, 2023, balances of loan from a former director of SensaSure were $26,850 (SEK300,000) and $29,232 (SEK300,000), respectively. The loan is unsecured, bearing interest at 2% per annum and due on demand. The interest expense was $278 and $319 for six months ended October 31, 2023 and 2022, respectively.

(c)	Payables and interest accrual to a related party

The accounts payable balance related to professional services provided by a vendor that is controlled by a then-director of Sensa Bues AB.

As at October 31, 2023 and 2022, the interest accrual balance related to overdue invoices from the related party vendor was $138,483 and was included in accounts payable and accrued liabilities to a related party.

As at October 31, 2023, the total accounts payable and accrued liabilities to the related party was $470,445 (April 30, 2023 - $486,826).

For the six months ended October 31, 2023, the total purchase from the related party representing the research and development and patent expenses was in amount of $10,145 (October 31, 2022 - $19,421).

On March 30, 2021, Sensa Bues AB, through a settlement agreement with the vendor, modified the payment term of accounts payable balance related to professional services provided in the amount of $333,744 (SEK2,798,280), and the parties agreed to settle the accounts payable balance in seven installments (Note 2 (c)) and the payable balance became current on April 30, 2023. Management has evaluated the terms of the agreement in accordance with the guidance provided by ASC 470 and concluded that there was no extinguishment accounting applicable to the modification. The payment modification did not include overdue invoices related interest accruals. At October 31, 2023, the accounts payable balance related to professional services provided by the related party vendor that was not included in the above settlement was $6,701 (April 30, 2023 - $6,701).

At October 31, 2023, the current portion of the modified payable balance was $232,458 (April 30, 2023 - $240,012) and the long term portion was $nil (Aril 30, 2023 - $Nil).

F-13

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

8.	STOCKHOLDERS’ DEFICIENCY

(a)	Authorized and Issued Stock

At October 31, 2023, the Company is authorized to issue 250,000,000 (April 30, 2023 – 250,000,000) shares of common stock ($0.01 par value).

At October 31, 2023 and 2022, the Company is authorized to issue 5,000,000 (April 30, 2023 – 5,000,000) shares of Class A preferred stock ($0.001 par value). Class A preferred stock has a conversion rate of 1 to 1,000 common shares and such conversion can occur subject to various performance condition, service conditions and lock up period that will vary for each of the issuances. When conversion is available it shall be at the discretion of the preferred shareholder. Sale of the converted shares shall not occur until sixty (60) months after a NASDAQ listing. There shall be no dividend rights assigned to the Class A preferred shares. There shall be no registration rights attached to the converted shares. Voting rights per preferred share are 1,000 common shares.

At October 31, 2023, the Company is authorized to issue 5,000,000 (April 30, 2023– 5,000,000) shares of Class B preferred stock ($0.001 par value). Class B preferred stock has a conversion rate of 1 to 1,000 common shares and such conversion can occur subject to various performance condition, service conditions and lock up period that will vary for each of the issuances. There shall be no dividend rights assigned to the Class B preferred shares. There shall be no registration rights attached to the converted shares. Vested common shares may become free trading when certain conditions are met. Each consultant to be advised of their specific conditions that must be met. Voting rights per share are equal to 1,000 common votes for each preferred share.

At October 31, 2023, common shares issued and outstanding totaled 56,349,183 (April 30, 2023 – 56,349,183) shares (Note 8 (b)).

At October 31, 2023, there were Nil Class A shares of Preferred Stock that were issued and outstanding (April 30, 2023 – Nil) (Note 8 (b)).

At October 31, 2023, there were Nil Class B shares of Preferred Stock that were issued and outstanding (April 30, 2023 – Nil) (Note 8 (b)).

(b)	Share issuance

Share issuance during the year ended April 30, 2021

During the year ended April 30, 2021, Sensa Bues AB, via a private placement for proceeds of $99,643, issued 10,000 common shares to SensaSure. SensaSure’s common stock has been adjusted retroactively to give effect for the exchange ratio upon the issuance and resulted in issuance of 499,935 shares of common stock of SensaSure. The proceeds received was reflected as an increase in common stock in amount of $4,999 and additional paid-in capital in amount of $94,644, respectively.

On December 21, 2020, the Company completed a reverse recapitalization via a share exchange agreement with Sensa Bues AB and the shareholders who owned 270,339 common shares that represented 72.82% of the total issued and outstanding common shares in Sensa Bues AB. Under the share exchange agreement, the shareholders of Sensa Bues AB, agreed to exchange their shares of Sensa Bues AB for common shares of SensaSure at an exchange ratio of approximate 1:49.99. Pursuant to the share exchange transactions (see share exchange agreement noted above), SensaSure issued a total of 13,515,183 common shares and the then-shareholders of Sensa Bues AB hold their ownership of Sensa Bues AB through SensaSure. (Note 1). Shareholders agreed that from the Effective Date of share exchange agreement the Shareholders shall have up to 243,402 shares to sell when a trading market begins on the OTC Markets. Eighteen (18) months after the initial listing date of the shares on the NASDAQ Market, the Shareholder shall have 1,914,704 shares available to sell. Twenty-four (24) months after the initial listing date of the shares on the NASDAQ Market, the Shareholders shall have 5,744,109 shares available to sell. Any remaining shares held by the Shareholders may be sold subject to Rule 144 trading requirements and Officer/Director restrictions, if applicable. The Shareholders will not (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any of the Securities or any securities convertible into, exercisable or exchangeable for or that represent the right to receive shares of Common Stock (including, without limitation, shares of Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired, or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise; Shareholders further agreed that any sale of the Securities for twelve months following the end of the Lock Up Period shall be subject to the volume restrictions of Rule 144.

F-14

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

During the year ended April 30, 2021, Sensa Bues AB, via several private placements for proceeds of $27,671, issued 93,032 common shares to noncontrolling interests (Note 8 (c)). The proceeds were reflected as an increase of $27,671 in noncontrolling interests.

During the year ended April 30, 2021, SensaSure acquired an additional 267,296 common shares (Note 8 (c)) of Sensa Bues AB for cash consideration of $80,800. The additional investment in Sensa Bues AB and the corresponding increase in Sensa Bues AB’ share capital was eliminated upon consolidation and had no cash flow impact.

During the year ended April 30, 2021, SensaSure, via several private placements with proceeds of $793,000 for 12,200,000 restricted common shares, issued 11,780,000 common shares. The proceeds received was reflected as an increase in common stock in amount of $117,800 and additional paid-in capital in amount of $647,900 respectively. The Company recognized a subscription receivable in amount of $27,300 as well as shares to be issued at April 30, 2021. The number of shares to be issued was 420,000. The Company received the subscription proceeds subsequently to year end and issued 420,000 common shares accordingly (Note 4). The subscribers entered into lock up agreement pursuant to which (1) The Shareholders shall 1,715,800 of the shares subscribed to sell when a trading market begins on the OTC Markets; (ii) The Shareholders shall have 5,346,000 of their remaining shares available to sell Six (6) months after the initial listing date of the shares on the NASDAQ Market; (iii) The Shareholders shall have their remaining shares for trading Eighteen (18) months after the initial listing date of the shares on the NASDAQ Market; and (iv) In the event the stock does not begin trading on the NASDAQ Market within a period of Thirty-Six (36) months after the execution of the Share Exchange Agreement, the Shareholders shall have up to Thirty Percent (30%) of their remaining shares available to sell after the initial listing date of the shares on the OTC Market. The balance of the Shareholder’s shares shall be available for trading Sixty (60) months after the initial listing date of the shares on the OTC Market (the “Lock Up Period”).

During year ended April 30, 2022, the Company has revised the lock up periods of certain shareholders, resulting in a change of total number of shares to be released at different time. This process was completed on April 4, 2022. After the revision, the shareholders shall have 10,898,736 shares available to sell upon a trading market begins on OTC Market, 7,738,000 shares available to sell upon six months after a trading market begins on OTC Market, 4,750,000 shares available to sell upon initial listing date on the Nasdaq Market, 6,280,000 shares available to sell upon six months after initial listing date on the Nasdaq Market, 800,000 shares available to sell upon twelve months after initial listing date on the Nasdaq Market, 3,838,213 shares available to sell upon eighteen months after the initial listing date on Nasdaq Market, 6,620,863 shares available to sell upon twenty four months after the initial listing date on Nasdaq Market and the balance of the shareholders’ shares will be available to sell upon sixty months after the initial listing date on Nasdaq Market. Shareholders further agreed that any sale of the Securities for twelve months following the end of the Lock Up Period shall be subject to the volume restrictions of Rule 144.

During the year ended April 30, 2021, SensaSure issued 22,000,000 common shares to directors of the Company for director services that starts from May 1, 2021 to April 30, 2026. If a director fails to complete the term of his responsibility the unearned portion of the shares shall be returned to the treasury stock of the Company. The fair value of the shares issued, in amount of $502,614, was determined by allocating the Enterprise Equity Value on a fully-diluted basis. During the year ended April 30, 2022, three directors left the Company and the 7,931,000 unvested shares was cancelled accordingly. The fair value of the vested portion of share based compensation expenses, in the amount of $88,210, was amortized and recorded in general and administrative expenses as well as an increase in common stock in amount of $38,610 and additional paid in capital in amount of $49,600 respectively during the year ended April 30, 2022. During December 2022, two directors left the Company and the 8,587,000 unvested shares was cancelled accordingly. The fair value of the vested portion of share based compensation expenses, in the amount of $36,440, was amortized and recorded in general and administrative expenses as well as an increase in common stock in amount of $15,950 and additional paid in capital in amount of $20,490 respectively during the year ended April 30, 2023.

During the year ended April 30, 2021, SensaSure issued 24,371 Class A Preferred Stock to directors of the Company for services provided. The fair value of the shares issued, in amount of $360,795, was determined based on the common stock fair value and factoring in the conversion rights which are subject to performance condition. Estimates of the timing and successful completion of the performance conditions were made by management. The fair value of the shares issued was recorded as share-based compensation and included in general and administrative expenses with a credit of $24 and $360,771 in Class A Preferred Stock and additional paid-in capital, respectively.

F-15

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

On January 31, 2022, the board of directors of the Company has discussed and approved the conversion of the classes A preferred stock to be done prior to filing an application to the OTC Markets for trading on the OTC Markets ATS. Conversion was completed on January 31, 2022 and Class A preferred stock were converted into 24,371,000 of common shares of the Company. All service conditions and lock up period applied to each of the issuances remained unchanged. During December 2022, upon a voluntarily surrender from a director of the Company, the Company cancelled 21,637,000 common shares that were converted from Class A Preferred Stock during year ended April 30, 2022, and $216,370 was reduced from common stock and transferred to additional paid-in capital.

During the year ended April 30, 2021, SensaSure issued 31,500 Class B Preferred Stock to directors and consultants of the Company for services to be provided. The fair value of the shares issued, in amount of $502,952, was determined based on the common stock fair value and factoring in the conversion rights which are subject to performance conditions. Estimates of the timing and successful completion of the performance conditions were made by management. The fair value will be recorded as an expense as well as an increase in Class B Preferred Stock and additional paid-in capital upon satisfaction of the vesting conditions.

During December 2022, upon a voluntarily surrender from a director of the Company, the Company cancelled 27,950,000 common shares that were converted from Class B Preferred Stock during year ended April 30, 2022.

During the year ended April 30, 2021, the Company, Sensa Bues AB and a director of the Company reached an agreement to settle accounts payable in the amount of $326,337 by issuing options to purchase common shares of Sensa Bues AB with a guarantee of subscription of the Company’s common shares upon exercise of the option by the optionee (Note 2 (c) and Note 7 (a)). The fair value of the stock option was determined based on the fair value of the services provided by the director. The difference between the carrying amount of the liability settled and the fair value of options issued is $nil. The term of the Agreement is for thirty-six months from March 31, 2021. The Company guaranteed that it shall purchase shares of the optionee during the term of the agreement based on the formula of 50 common shares of the Company for each one shares the optionee subscribed of Sensa Bues AB.

Share issuance during the year ended April 30, 2022

The Company recognized a subscription receivable in amount of $27,300 as well as shares to be issued at April 30, 2021. The number of shares to be issued was 420,000. The Company received the subscription proceeds during the year ended April 30, 2022 and issued 420,000 common shares accordingly (Note 4).

During the year ended April 30, 2022, SensaSure, via several private placements, raised proceeds of $340,900 ($0.07 per share) and issued 4,870,000 common shares. The proceeds received was reflected as an increase in common stock in amount of $48,700 and additional paid-in capital in amount of $292,200 respectively. The subscribers entered into lock up agreement and the shareholders shall have 502,584 shares available to sell upon a trading market begins on OTC Market, 356,484 shares available to sell upon six months after a trading market begins on OTC Market, 218,663 shares available to sell upon initial listing date on the Nasdaq Market, 289,278 shares available to sell upon six months after initial listing date on the Nasdaq Market, 37,012 shares available to sell upon twelve months after initial listing date on the Nasdaq Market, 176,781 shares available to sell upon eighteen months after the initial listing date on Nasdaq Market, 304,862 shares available to sell upon twenty four months after the initial listing date on Nasdaq Market and the balance of the shareholders’ shares will be available to sell upon sixty months after the initial listing date on Nasdaq Market.

During the year ended April 30, 2022, the Company approved the issuance of 2,118,000 shares of the common stock to several consultants and directors. The fair value of the share-based compensation was in the amount of $148,260 and was included in the general and admirative expenses as well as a credit made in common stock in amount of 21,180 and additional paid-in capital in amount of 127,080 respectively. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. One of the consultants is a related party individual and the share awards was 2,100,000 common shares with an amount of 147,000.

During the year ended April 30, 2022, SensaSure issued 3,080,000 common stock to a consultant of the Company for services to be provided in future including completion of certain financing projects and regulatory services. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. At April 30, 2022 and 2023, none of these services were rendered. Accordingly, the Company has not recognized any share based compensation expense during the year.

F-16

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

Share issuance and shares to be issued during the year ended April 30, 2023

During the year ended April 30, 2023, included into shares to be issued were 54,000 common stock for services provided by the directors. The fair value of the share-based compensation was in the amount of $3,780 and was determined by using the most recent private placement price at $0.07 per share. The fair value of the share-based compensation was included in the general and admirative expenses as well as a credit made in shares to be issued.

On January 31, 2022, the board of directors of the Company has discussed and approved the conversion of the classes B preferred stock to be done prior to filing an application to the OTC Markets for trading on the OTC Markets ATS. Conversion was completed on January 31, 2022 and Class B preferred stock were converted into 31,500,000 of common shares of the Company. All service conditions and lock up period applied to each of the issuances remained unchanged. As at April 30, 2023, 750,000 common shares related service conditions were met and the Company included 750,000 common shares into shares to be issued. The fair value of the share-based compensation was in the amount of $11,975. The fair value of the share-based compensation was included in the general and admirative expenses as well as a credit made in shares to be issued.

During the three months ended July 31, 2022, SensaSure acquired an additional 2,200,000 common shares of Sensa Bues AB for cash consideration of $225,641. The additional investment in Sensa Bues AB and the corresponding increase in Sensa Bues AB’ share capital was eliminated upon consolidation and had no cash flow impact.

During the three months ended January 31, 2023, the Company approved the issuance of 8,800,000 shares of the common stock to a director of the Company. The shares issued would be vested in a 24-month term with a date of commencement at December 15, 2022. During year ended April 30, 2023, 1,650,000 common shares vested and the fair value of the share-based compensation was in the amount of $115,500 and was included in the general and admirative expenses as well as a credit made in common stock in amount of 16,500 and additional paid-in capital in amount of 99,000 respectively. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. For six months ended October 31, 2023, there were 2,200,000 number of shares vested and the Company recorded $22,000 and $132,000 into common stock and additional paid-in capital respectively.

During the year ended April 30, 2021, the Company issued 22,000,000 common shares to the directors. Those common shares issued were subject to a 60 months service period. The detailed accounting treatment for those issued but unvested shares are as below:

			Common shares vested						Common shares cancelled upon resignation							At year end			At year end		At year		At year end
	Common shares issued		Common shares		Common Stock		Additional paid-in Capital		Common shares			Common Stock		Additional paid-in Capital		Common shares outstanding			Common shares vested		end Common Stock		Additional paid-in Capital
	Shares		Shares		$		$		Shares			$		$		Shares			Shares		$		$
At April 30, 2021		22,000,000		-		-		-		-			-		-		22,000,000			-		-		-
Amortization of vested shares		-		3,861,000		38,610		49,600					-		-		-			3,861,000		38,610		49,600
Cancellation of common shares		-		-		-		-		(7,931,000	)		-		-		(7,931,000	)		-		-		-
At April 30, 2022		22,000,000		3,861,000		38,610		49,600		(7,931,000	)		-		-		14,069,000			3,861,000		38,610		49,600
Amortization of vested shares		-		1,621,000.00		15,950		20,490		-			-		-		-			1,621,000		15,950		20,490
Cancellation of common shares		-		0.00		0.00		0.00		(8,587,000	)		-		-		(8,587,000	)		-		-		-
At April 30, 2023		22,000,000		5,482,000		54,560		70,090		(16,518,000	)		-		-		5,482,000			5,482,000		54,560		70,090

At April 30, 2023, there were 2,800,000 unvested common shares that was converted from Class B shares of Preferred Stock during year ended April 30, 2022. At April 30, 2023, there were 750,000 vested and to be issued common shares that was converted from Class B shares of Preferred Stock during year ended April 30, 2022. The dollar value associated with those shares in the amount of $35,500 was not included in the common stock.

For six months ended October 31, 2022, there were 1,276,000 number of shares vested and the Company recorded $12,760 and $16,392 into common stock and additional paid-in capital respectively.

F-17

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

At October 31, 2023 and April 30, 2023, there were 4,950,000 and 7,150,000 unvested common shares that was issued to the director of the Company respectively. The dollar value associated with those unvested shares in the amount of $49,500 (April 30, 2023 - $71,500) was not included in the common stock.

At October 31, 2023 and April 30, 2023, there were 3,080,000 unvested common shares that was issued to a consultant of the Company. The dollar value associated with those unvested shares in the amount of $30,800 was not included in the common stock.

(c)	Noncontrolling interest

During the six months ended October 31, 2023 and 2022, pursuant to private placements completed by Sensa Bues AB, the Company’s ownership interests and noncontrolling interests’ ownership in Sensa Bues AB changed as below:

	As At		As At		As At		As At
	October 31,		April 30,		October 31,		April 30,
	2023		2023		2022		2022
	(%)		(%)		(%)		(%)
Ownership percentage
Common shareholders of the Company		93.53		93.53		93.53		74.00
Noncontrolling interests		6.47		6.47		6.47		26.00

	For the quarter		For the quarter
	ended		ended
	October 31,		October 31,
	2023		2022
	$		$
Transfer from noncontrolling interests
Increase in the Company’s accumulated deficit for Sensa Bues AB issuance of common shares to the Company and noncontrolling interests (Note 8 (b))		-		(883,768	)
Change from net loss attributable to the Company and transfer from noncontrolling interests		-		(883,768	)

(d)	Development reserve

In compliance with the Swedish Annual. Accounts Act (the “Act”), SensaBues financial statements recognize a development reserve. This reserve is considered restricted and is not distributable as dividends. SensaBues can transfer from the balance of development reserve to accumulated deficit those amounts to the extent of those qualified expenses that occurred in the prior year. For the year ended April 30, 2023, SensaBues transferred $59,804 from development reserve to accumulated deficits (2022 – $108,102). For the six months ended October 31, 2023, SensaBues transferred $Nil from development reserve to accumulated deficits

F-18

SENSASURE TECHNOLOGIES, INC.

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 AND 2022

(continued)

9.	CONTINGENCY

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As at October 31, 2023 and April 30, 2023 there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party or has a material interest adverse to the Company’s interest.

10.

SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events up to December 15, 2023, the date the consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events that are needed to be disclosed:

Subsequent to the six months ended October 31, 2023, due to the difficulties in raising adequate capital, the significant cost of maintaining the patents, and delays in engaging appropriate commercialization partners, the management of the Company believe that the current business of commercializing the exhale breath technology patents is no longer feasible. The management of the Company is in the process of establishing a new business segment to develop energy and energy related businesses and proceed to wind up its Swedish subsidiary, Sensabues AB.

On December 11, 2023, the Company and Formation Minerals Inc., a Nevada corporation and a wholly-owned subsidiary of the Parent (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Verde Bio Holdings, Inc., a Nevada corporation (the “Verde”).

Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein upon the consummation of the transactions contemplated by the Merger Agreement (the “Closing”), Verde will merge with and into the Merger Sub (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Transactions”), with Merger Sub continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of the Company. In the Merger, all of the issued and outstanding capital stock of Verde immediately prior to the Effective Time shall no longer be outstanding and shall automatically be cancelled and shall cease to exist in exchange for the right for Verde’s stockholders to receive the Merger Consideration Shares. In consideration for the Merger, Verde’s stockholders shall be entitled to receive from the Company, shares of capital stock of the Company based upon the exchange ratios set forth in the Merger Agreement (collectively, the “Merger Consideration Shares”).

F-19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company,” “Sensasure,” “our,” “us” or “we” refer to Sensasure Technologies Inc. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other U.S. Securities and Exchange Commission (“SEC”) filings.

Overview

SensaSure is a medical technology or “MedTech”, company supplying a simple device and method to collect a breath sample for lab-based analysis. Exhaled breath contains aerosols which originate from the lungs and blood. These aerosols contain revealing information for analytics, diagnostics, and therapeutics. SensaSure’s patented method is called ExaBreath (EB) and it can collect, extract, detect and identify non-volatile compounds present in every exhaled breath by utilizing existing lab-based testing infrastructure and procedures. EB is applicable in toxicology, pharmacology, and clinical biochemistry. We have not applied for, nor has our EB device received approval from any government agency in the European Union or from the U.S. Food and Drug Administration (“FDA”). We can provide no assurance that any government regulatory body will clear our EB device for commercial use.

We believe EB may enhance the overall user experience in a wide range of applications and markets such as workplace drug testing, anti-doping in sport, law enforcement, e-health, and telemedicine. In the case of anti-doping, EB may reduce the time, cost, and overall burden that drug programs place on athletes, other participants, and the wider stakeholders such as leagues and associations. EB may improve the user experience for both donors and collectors during sample collection process.

Drug control programs represent significant market segments due to the necessity of testing in most sports, industries, law enforcement agencies, ministries, police forces, criminal justice systems and by many employers for the insurance industry.

We believe that our business model will follow a methodology to try to reduce risks, including transferring the manufacturing costs to third parties to reduce capital investment which we hope will provide relatively higher margin business based upon our EB collection device to improve user acceptability and analytical credibility in areas such as anti-doping in sport. We expect that this will increase the credibility and perceived value of doping control programs resulting in a stronger deterrence factor and better protection for the integrity of sport.

The global device market in drug testing is estimated to be nearly $4.5 billion in 2020 and is estimated to reach $10 billion by 2025 (According to BCC Research, Drug Testing Market Report 2019). The estimates provided here are based on varying estimates from research companies and actual numbers may vary significantly. While there are several basic types of drug tests, the most common method is urine testing.

Current Challenges

Our New Business Segment and Ongoing Development

We intend to establish a new business segment to develop energy and energy related businesses. On October 30, 2023, we entered into a contractor agreement with Verde Bio Holdings, Inc., a Nevada corporation (“Verde”) to conduct feasibility studies and establish commercial relationships to enter into energy and energy related businesses. The initial term of the agreement is three (3) months, and we shall pay Verde $100,000 in cash or its equivalent in restricted shares of common stock of the Company.

Critical accounting policies

The unaudited condensed consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States Dollars. Significant accounting policies are summarized below:

(a)	Revenue recognition

The Company sells devices with collection mechanism for biological samples based upon exhaled breath. Revenue comprises devices delivered to the Company’s customers.

The principles in ASC 606 are applied using the following five steps:

Identify the contract with a customer;

Identify the performance obligation(s) in the contract;

Determine the transaction price;

Allocate the transaction price to the performance obligation(s) in the contract; and

Recognize revenue when (or as) the performance obligation(s) are satisfied.

(b)	Cash and restricted cash held in trust

(c)	Non-controlling interests

(d)	Critical management judgment and use of estimates

(e)	Accounts receivable

(f)	Research and development

Research and development and all patent maintenance and related filing costs are charged to operations as incurred as the Company is uncertain as to any future economic benefit.

(g)	Stock based compensation

(h)	Foreign Currency Translation

(i)	Fair Value of financial instruments

●

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

●

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

●

(j)	Income Taxes

(k)	Loss per share

(l)	Operating Segments

(m)	Recently issued accounting pronouncements

The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Results of Operations

Consolidated Financial Position

As of October 31, 2023 we have Total Assets of $15,358 compared to $39,646 at April 30, 2023. The decrease of $24,288 during the six month period is due primarily to the decrease in our cash and restricted cash held in trust. Our Total Assets consist of Current Assets only.

Our Current Liabilities as of October 31, 2023 are $1,165,528 compared to $1,101,239 at April 30, 2023. The increase in our current liabilities of $64,289 is mainly attributed to an increase in amount due to related parties (see note 7 of unaudited interim condensed consolidated financial statements). We have no long term liabilities at October 31, 2023 and April 30, 2023.

The following table is from our unaudited condensed interim balance sheet as of October 31, 2023.

	At Octobe 31, 2023 (unaudited)			At April 30, 2023 (audited)
	$			$
ASSETS
Current assets:
Cash		3,135			26,786
Restricted cash held in trust		-			172
Accounts receivable		788			-
Subscription receivable		-			-
Prepayments and other receivables		11,435			12,688
Total current assets		15,358			39,646
Total assets		15,358			39,646

LIABILITIES AND STOCKHOLDERS’ DEFIECIENCY
Current liabilities:
Accounts payable and accrued liabilities		109,579			105,868
Accounts payable and accrued liabilities to a related party		470,445			486,826
Demand Loans		137,694			113,375
Loans from related parties		76,074			82,823
Amount due to related parties		371,736			312,347
Total current liabilities		1,165,528			1,101,239

Total liabilities		1,165,528			1,101,239

STOCKHOLDERS’ DEFICIECY
Class A Preferred stock, $0.001 par value, 5,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding shares: Nil and Nil as at October 31, 2023 and April 30, 2023, respectively.		-			-
Class B Preferred stock, $0.001 par value, 5,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding shares: Nil and Nil as at October 31, 2023 and April 30, 2023, respectively.		-			-
Common stock, $0.01 par value, 250,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding common shares: and 56,349,183 as at October 31, 2023 and 56,349,183 at April 30, 2023, respectively.		447,431			425,431
Shares to be issued (804,000 and 804,000 common shares at October, 2023 and April 30, 2023 respectively)		15,755			15,755
Additional paid-in capital		4,665,073			4,533,073
Foreign currency translation reserve		(170,131	)		(231,505	)
Accumulated deficit		(6,334,768	)		(6,027,209	)
Total deficit attributable to equity holders of the Company		(1,376,640	)		(1,284,455	)
Total equity attributable to non-controlling interests		45,669			42,061
Development reserve		180,801			180,801
Total deficit		(1,150,170	)		(1,061,593	)
Total liabilities and stockholders’ deficiency		15,358			39,646

Consolidated Results of Operations

Comparative Results for the three months ended October 31, 2023 and 2022

The Company had revenue from sales for the three months period ended October 31, 2023 of $811. The loss per share, both basic and diluted, was $0.003 (October 31, 2022 – $0.001). This was anticipated by the Company since the efforts of the Company have been focused on commercialization of the technologies and maintaining operations.

For the three months period ended October 31, 2023 we had a revenue of $811 which is an increase in revenue from the same period ended October 31, 2022 which had a revenue in the amount of $680.

Our total general administrative expenses and research and development expenses have decreased and were in the amount of $157,698 (October 31, 2022 - $152,062).

Comparative Results for the six months ended October 31, 2023 and 2022

The Company had revenue from sales for the six months period ended October 31, 2023 of $1,146. The loss per share, both basic and diluted, was $0.005 (October 31, 2022 – $0.003). This was anticipated by the Company since the efforts of the Company have been focused on commercialization of the technologies and maintaining operations.

For the six months period ended October 31, 2023 we had a revenue of $1,146 which is an decrease in revenue from the same period ended October 31, 2022 which had a revenue in the amount of $4,414. This was due to the delays in engaging appropriate commercialization partners to develop exhale breath technology.

Our total general administrative expenses and research and development expenses have decreased and were in the amount of $306,497 (October 31, 2022 - $333,330). The reduction in costs is largely due to savings in legal and other overhead expenses.

The following provides the details for the results of our operations for the periods ended October 31, 2023 and 2022.

	Three Months Ended October 31, 2023 (unaudited)			Three Months Ended October 31, 2022 (unaudited)			Six Months Ended October 31, 2023 (unaudited)			Six Months Ended October 31, 2022 (unaudited)
	$			$			$			$

Revenue		811			680			1,146			4,414

Expenses
General and administrative expense		(154,467	)		(132,641	)		(296,352	)		(313,909	)
Research and development expense		(3,231	)		(19,421	)		(10,145	)		(19,421	)
TOTAL OPERATING EXPENSES		(157,698	)		(152,062	)		(306,497	)		(333,330	)

Interest expenses, net		(1,968	)		(1,995	)		(4,009	)		(4,132	)
Other income (expenses), net
NET LOSS BEFORE INCOME TAXES		(158,855	)		(153,377	)		(309,360	)		(333,048	)
Income taxes
NET LOSS		(158,855	)		(153,377	)		(309,360	)		(333,048	)
Less: net loss attributable to non-controlling interests		164			4,277			1,801			5,797
Net loss attributable to the Company		(158,691	)		(149,100	)		(307,559	)		(327,251	)

Basic and diluted loss per share		(0.003	)		(0.001	)		(0.005	)		(0.003	)

Weighted average number of common shares outstanding		56,349,183			105,723,183			56,349,183			105,723,183

The condensed interim consolidated statements of comprehensive loss for the three months ended October 31, 2023 over 2022 in the table below reflect the total comprehensive loss for the period and the amount attributable to common shareholders and non- controlling interests.

	Three Months Ended October 31, 2023 (unaudited)			Three Months Ended October 31, 2022 (unaudited)			Six Months Ended October 31, 2023 (unaudited)			Six Months Ended October 31, 2022 (unaudited)
	$			$			$			$

Net loss for the period		(158,855	)		(153,377	)		(309,360	)		(333,048	)
Foreign currency translation adjustments		48,585			61,005			66,783			73,357
Total comprehensive loss for the period		(110,270	)		(92,372	)		(242,577	)		(259,691	)

Attributable to:
Net loss attributable to the Company		(158,691	)		(149,100	)		(307,559	)		(327,251	)
Foreign currency translation adjustments attributable to the Company		44,353			57,058			61,374			68,612
Net loss attributable to non-controlling interests		(164	)		(4,277	)		(1,801	)		(5,797	)
Foreign currency translation adjustments attributable to non-controlling interests		4,232			3,947			5,409			4,745
		(110,270	)		(92,372	)		(242,577	)		(259,691	)

At October 31, 2023 we have a total of 56,349,183 shares of common stock outstanding.

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Foreign Currency Translation Reserve			Accumulated deficit			(Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		$		Shares		$		Shares		$		Shares		$		$		$			$			$			$			$		$
Balance at July 31, 2023 (unaudited)				56,349,183		436,431		-		-		-		-		804,000		15,755		4,599,073		(214,484	)		(6,176,077	)		(1,339,302	)		41,601			180,801		(1,116,900	)
Amortization of vested shares		8		-		11,000		-		-		-		-		-		-		66,000		-			-			77,000			-			-		77,000
Loss for the period				-		-		-		-		-		-		-		-		-		-			(158,691	)		(158,691	)		(164	)		-		(158,855	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		44,353			-			44,353			4,232			-		48,585
Balance at October 31, 2023 (unaudited)				56,349,183		447,431		-		-		-		-		804,000		15,755		4,665,073		(170,131	)		(6,334,768	)		(1,376,640	)		45,669			180,801		(1,150,170	)

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Accumulated Other Comprehensive Loss			Accumulated deficit			(Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		US$		Shares		US$		Shares		US$		Shares		US$		US$		US$			US$			US$			US$			US$		US$
Balance at July 31, 2022 (unaudited)				105,723,183		615,731		-		-		-		-		-		-		4,205,409		(235,688	)		(5,495,271	)		(909,819	)		53,275			240,641		(615,903	)
Amortization of vested shares		8		-		6,380		-		-		-		-		-		-		8,196		-			-			14,576			-			-		14,576
Issuance of common shares for service		8		-		-		-		-		-		-		36,000		2,520		-		-			-			2,520			-			-		2,520
Loss for the period				-		-		-		-		-		-		-		-		-		-			(149,100	)		(149,100	)		(4,277	)		-		(153,377	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		57,058			-			57,058			3,947			-		61,005
Balance at October 31, 2022 (unaudited)				105,723,183		622,111		-		-		-		-		36,000		2,520		4,213,605		(178,630	)		(5,644,371	)		(984,765	)		52,945			240,641		(691,179	)

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Foreign Currency Translation Reserve			Accumulated deficit			(Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		$		Shares		$		Shares		$		Shares		$		$		$			$			$			$			$		$
Balance at April 30, 2023 (audited)				56,349,183		425,431		-		-		-		-		804,000		15,755		4,533,073		(231,505	)		(6,027,209	)		(1,284,455	)		42,061			180,801		(1,061,593	)
Amortization of vested shares		8		-		22,000		-		-		-		-		-		-		132,000		-			-			154,000			-			-		154,000
Loss for the period				-		-		-		-		-		-		-		-		-		-			(307,559	)		(307,559	)		(1,801	)		-		(309,360	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		61,374			-			61,374			5,409			-		66,783
Balance at October 31, 2023 (unaudited)				56,349,183		447,431		-		-		-		-		804,000		15,755		4,665,073		(170,131	)		(6,334,768	)		(1,376,640	)		45,669			180,801		(1,150,170	)

			Common Stock				Class A Preferred Stock				Class B Preferred Stock				Shares to be issued				Additional paid-in Capital		Accumulated Other Comprehensive Loss			Accumulated deficit			Equity (Deficit)			Non- controlling interests			Development Reserve		Total
	Note		Shares		US$		Shares		US$		Shares		US$		Shares		US$		US$		US$			US$			US$			US$			US$		US$
Balance at April 30, 2022 (audited)				105,723,183		609,351		-		-		-		-		-		-		4,197,213		(195,610	)		(4,433,352	)		177,602			(881,448	)		240,641		(463,205	)
Subsidiary issuance of shares pursuant to private placement		8		-		-		-		-		-		-		-		-		-		-			-			-			45			-		45
Amortization of vested shares		8		-		12,760		-		-		-		-		-		-		16,392		-			-			29,152			-			-		29,152
Issuance of common shares for service		8		-		-		-		-		-		-		36,000		2,520		-		-			-			2,520.00			-			-		2,520
Loss for the period				-		-		-		-		-		-		-		-		-		-			(327,251	)		(327,251	)		(5,797	)		-		(333,048	)
Foreign translation adjustment				-		-		-		-		-		-		-		-		-		68,612			-			68,612			4,745			-		73,357
Effect of dilution of ownership in subsidiary pursuant to issuance of shares		8		-		-		-		-		-		-		-		-		-		(51,632	)		(883,768	)		(935,400	)		935,400			-		-
Balance at October 31, 2022 (unaudited)				105,723,183		622,111		-		-		-		-		36,000		2,520		4,213,605		(178,630	)		(5,644,371	)		(984,765	)		52,945			240,641		(691,179	)

Due to the difficulties in raising adequate capital, the significant cost of maintaining the patents, and delays in engaging appropriate commercialization partners, we believe that the current business of commercializing the exhale breath technology patents is no longer feasible. We intend to establish a new business segment to develop energy and energy related businesses and proceed to wind up its Swedish subsidiary, Sensabues AB. We believe that it will be necessary to sell additional shares to have the funds necessary to continue to pay the legal and accounting fees as the Company continues the process to have its shares trading in a public market. In addition, we may use additional shares to pursue the development of the new business segment.

Liquidity and Capital Resources

Our cash flows used in operating activities for the six month period ended October 31, 2023 compared to the same period in 2022 reflects a decrease of $206,793 net cash used in operating activities. Our net cash provided by financing activities reflects an increase of $70,234 for the six month period ended October 31, 2023 compared to the same period in 2022. Cash and restricted cash held in trust at the beginning of the period ended October 31, 2023 was $26,958 compared to $437,177 Cash and restricted cash held in trust at the beginning of the same period in 2022. Cash and restricted cash held in trust at the end of the period ended October 31, 2023 was $3,135 compared to $148,640 Cash and restricted cash held in trust at the end of the same period in 2022.

We believe that it will be necessary to raise additional cash to continue to pay the legal and accounting fees as the Company continues the process to have its shares trading in a public market. In addition, Company may use additional shares to pursue the development of the new business segment.

The table below provides the unaudited condensed interim consolidated statements of cash flows for the six months ended October 31, 2023 and 2022.

	Six Months			Six Months
	Ended			Ended
	October 31,			October 31,
	2023			2022
	(unaudited)			(unaudited)
	$			$
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(309,360	)		(333,048	)
Adjustments for:
Amortization of vested shares		154,000			29,152
Issuance of shares for services		-			2,520
Changes in:
Accounts receivable		(788	)		(2,089	)
Prepayments and other receivables		1,253			(1,750
Accounts payable and accrued liabilities to third parties and a related party		(12,670	)		(43,363	)
Amounts due to related parties		59,389			51,544
Long term payable to a related party		-			(17,935	)
Net cash used in operating activities		(108,176	)		(314,969	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from subsidiary issuance of shares to noncontrolling interests		-			45
Proceeds from related party loans		70,279			-
Net cash provided by financing activities		70,279			45

Effect of exchange rate changes on cash and restricted cash held in trust		14,074			26,387
Net decrease in cash and restricted cash held in trust		(23,823	)		(288,537	)
Cash and restricted cash held in trust at the beginning of period		26,958			437,177
Cash and restricted cash held in trust at the end of period		3,135			148,640

Supplemental cash flows information
Income tax paid		-			-
Interest paid		-			-

Critical Accounting Policies and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. During the six month period ended October 31, 2023, we have made no material changes or additions with regard to such estimates and judgments.

Off-Balance Sheet Arrangements

As of October 31, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations, save and except for the $100,000 in cash or its equivalent in restricted shares of common stock of the Company payable to Verde Bio Holdings, Inc.

JOBS Act

On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We will qualify as an “emerging growth company” and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

We have not engaged in any hedging activities since our inception and we do not expect to engage in any hedging activities with respect to the market risk to which we are exposed.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of “disclosure controls and procedures” in Rule 13a-15(e). The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Company’s desired disclosure control objectives. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation.

At the end of the period being reported upon, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, as well as recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to the Company.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting that occurred during the six month period ended October 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

Factors that could cause our actual results to differ materially from those in this report include the risk factors described in our 10-K report filed with the SEC on August 14, 2023. As of the date of this Report, there have been no material changes to the risk factors disclosed in our final prospectus filed with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There have been no sales of the Securities of the Company for the financial reporting that occurred during the fiscal quarter ended October 31, 2023, covered by this Quarterly Report on Form 10-Q.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

The following exhibits are filed as part of this 10-Q:

Exhibit Number		Description

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Chief Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SENSASURE TECHNOLOGIES, INC.
(Registrant)

By:	/S/ JAMES HIZA	By:	/S/ JAMES HIZA
	James Hiza		James Hiza
	Chief Executive Officer		Acting Chief Financial Officer
	(Principal Executive Officer)		(Principal Financial and Accounting Officer)

Date:	December 18, 2023	Date:	December 18, 2023

NONE 0.001 0.003 0.003 0.005 false --04-30 Q2 2024 0001885336 0001885336 2023-05-01 2023-10-31 0001885336 2023-12-15 0001885336 2023-10-31 0001885336 2023-04-30 0001885336 us-gaap:PreferredClassAMember 2023-10-31 0001885336 us-gaap:PreferredClassAMember 2023-04-30 0001885336 us-gaap:PreferredClassBMember 2023-10-31 0001885336 us-gaap:PreferredClassBMember 2023-04-30 0001885336 2023-08-01 2023-10-31 0001885336 2022-08-01 2022-10-31 0001885336 2022-05-01 2022-10-31 0001885336 us-gaap:CommonStockMember 2023-07-30 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-07-30 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-07-30 0001885336 sesu:SharesToBeIssuedMember 2023-07-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2023-07-30 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2023-07-30 0001885336 us-gaap:RetainedEarningsMember 2023-07-30 0001885336 us-gaap:ParentMember 2023-07-30 0001885336 us-gaap:NoncontrollingInterestMember 2023-07-30 0001885336 sesu:DevelopmentReserveMember 2023-07-30 0001885336 2023-07-30 0001885336 us-gaap:CommonStockMember 2023-07-31 2023-10-30 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-07-31 2023-10-30 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-07-31 2023-10-30 0001885336 sesu:SharesToBeIssuedMember 2023-07-31 2023-10-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 2023-10-30 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2023-07-31 2023-10-30 0001885336 us-gaap:RetainedEarningsMember 2023-07-31 2023-10-30 0001885336 us-gaap:ParentMember 2023-07-31 2023-10-30 0001885336 us-gaap:NoncontrollingInterestMember 2023-07-31 2023-10-30 0001885336 sesu:DevelopmentReserveMember 2023-07-31 2023-10-30 0001885336 2023-07-31 2023-10-30 0001885336 us-gaap:CommonStockMember 2023-10-30 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-10-30 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-10-30 0001885336 sesu:SharesToBeIssuedMember 2023-10-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2023-10-30 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2023-10-30 0001885336 us-gaap:RetainedEarningsMember 2023-10-30 0001885336 us-gaap:ParentMember 2023-10-30 0001885336 us-gaap:NoncontrollingInterestMember 2023-10-30 0001885336 sesu:DevelopmentReserveMember 2023-10-30 0001885336 2023-10-30 0001885336 us-gaap:CommonStockMember 2022-07-31 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-07-31 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-07-31 0001885336 sesu:SharesToBeIssuedMember 2022-07-31 0001885336 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2022-07-31 0001885336 us-gaap:RetainedEarningsMember 2022-07-31 0001885336 us-gaap:ParentMember 2022-07-31 0001885336 us-gaap:NoncontrollingInterestMember 2022-07-31 0001885336 sesu:DevelopmentReserveMember 2022-07-31 0001885336 2022-07-31 0001885336 us-gaap:CommonStockMember 2022-08-01 2022-10-31 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-08-01 2022-10-31 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-08-01 2022-10-31 0001885336 sesu:SharesToBeIssuedMember 2022-08-01 2022-10-31 0001885336 us-gaap:AdditionalPaidInCapitalMember 2022-08-01 2022-10-31 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2022-08-01 2022-10-31 0001885336 us-gaap:RetainedEarningsMember 2022-08-01 2022-10-31 0001885336 us-gaap:ParentMember 2022-08-01 2022-10-31 0001885336 us-gaap:NoncontrollingInterestMember 2022-08-01 2022-10-31 0001885336 sesu:DevelopmentReserveMember 2022-08-01 2022-10-31 0001885336 us-gaap:CommonStockMember 2022-10-31 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-10-31 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-10-31 0001885336 sesu:SharesToBeIssuedMember 2022-10-31 0001885336 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2022-10-31 0001885336 us-gaap:RetainedEarningsMember 2022-10-31 0001885336 us-gaap:ParentMember 2022-10-31 0001885336 us-gaap:NoncontrollingInterestMember 2022-10-31 0001885336 sesu:DevelopmentReserveMember 2022-10-31 0001885336 2022-10-31 0001885336 us-gaap:CommonStockMember 2023-04-30 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-04-30 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-04-30 0001885336 sesu:SharesToBeIssuedMember 2023-04-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2023-04-30 0001885336 us-gaap:RetainedEarningsMember 2023-04-30 0001885336 us-gaap:ParentMember 2023-04-30 0001885336 us-gaap:NoncontrollingInterestMember 2023-04-30 0001885336 sesu:DevelopmentReserveMember 2023-04-30 0001885336 us-gaap:CommonStockMember 2023-05-01 2023-10-31 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-05-01 2023-10-31 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-05-01 2023-10-31 0001885336 sesu:SharesToBeIssuedMember 2023-05-01 2023-10-31 0001885336 us-gaap:AdditionalPaidInCapitalMember 2023-05-01 2023-10-31 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2023-05-01 2023-10-31 0001885336 us-gaap:RetainedEarningsMember 2023-05-01 2023-10-31 0001885336 us-gaap:ParentMember 2023-05-01 2023-10-31 0001885336 us-gaap:NoncontrollingInterestMember 2023-05-01 2023-10-31 0001885336 sesu:DevelopmentReserveMember 2023-05-01 2023-10-31 0001885336 us-gaap:CommonStockMember 2023-10-31 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-10-31 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-10-31 0001885336 sesu:SharesToBeIssuedMember 2023-10-31 0001885336 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2023-10-31 0001885336 us-gaap:RetainedEarningsMember 2023-10-31 0001885336 us-gaap:ParentMember 2023-10-31 0001885336 us-gaap:NoncontrollingInterestMember 2023-10-31 0001885336 sesu:DevelopmentReserveMember 2023-10-31 0001885336 us-gaap:CommonStockMember 2022-04-30 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-04-30 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-04-30 0001885336 sesu:SharesToBeIssuedMember 2022-04-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2022-04-30 0001885336 us-gaap:RetainedEarningsMember 2022-04-30 0001885336 us-gaap:ParentMember 2022-04-30 0001885336 us-gaap:NoncontrollingInterestMember 2022-04-30 0001885336 sesu:DevelopmentReserveMember 2022-04-30 0001885336 2022-04-30 0001885336 us-gaap:CommonStockMember 2022-05-01 2022-10-31 0001885336 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-05-01 2022-10-31 0001885336 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-05-01 2022-10-31 0001885336 sesu:SharesToBeIssuedMember 2022-05-01 2022-10-31 0001885336 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-10-31 0001885336 sesu:ForeignCurrencyTranslationReserveMember 2022-05-01 2022-10-31 0001885336 us-gaap:RetainedEarningsMember 2022-05-01 2022-10-31 0001885336 us-gaap:ParentMember 2022-05-01 2022-10-31 0001885336 us-gaap:NoncontrollingInterestMember 2022-05-01 2022-10-31 0001885336 sesu:DevelopmentReserveMember 2022-05-01 2022-10-31 0001885336 sesu:SensaSureTechnologiesIncMember 2020-09-08 0001885336 sesu:SensaSureTechnologiesIncMember us-gaap:CommonClassAMember 2020-09-08 0001885336 sesu:SensaSureTechnologiesIncMember us-gaap:CommonClassBMember 2020-09-08 0001885336 us-gaap:PrivatePlacementMember 2021-04-30 0001885336 us-gaap:PrivatePlacementMember 2021-04-01 2021-04-30 0001885336 us-gaap:CommonStockMember 2023-05-01 2023-10-31 0001885336 us-gaap:CommonStockMember 2023-04-30 2023-04-30 0001885336 us-gaap:CommonStockMember 2022-05-01 2022-10-31 0001885336 us-gaap:CommonStockMember 2022-04-30 2022-04-30 0001885336 sesu:LiquidityAndGoingConcernMember 2023-10-31 0001885336 sesu:LiquidityAndGoingConcernMember 2023-04-30 0001885336 2021-04-30 0001885336 2021-03-30 0001885336 2020-05-01 2021-04-30 0001885336 2021-05-01 2022-04-30 0001885336 sesu:SensaBuesABMember 2023-10-31 0001885336 sesu:SensaBuesABMember 2023-04-30 0001885336 sesu:SensaBuesABMember 2023-05-01 2023-10-31 0001885336 sesu:SensaBuesABMember 2022-05-01 2022-10-31 0001885336 srt:BoardOfDirectorsChairmanMember sesu:SensaBuesABMember 2023-05-01 2023-10-31 0001885336 srt:BoardOfDirectorsChairmanMember sesu:SensaBuesABMember 2022-05-01 2023-04-30 0001885336 us-gaap:RelatedPartyMember 2021-03-31 0001885336 2021-03-31 0001885336 2021-03-31 2021-03-31 0001885336 2022-05-01 2023-04-30 0001885336 srt:DirectorMember 2023-10-31 0001885336 srt:DirectorMember 2023-04-30 0001885336 srt:DirectorMember 2023-05-01 2023-10-31 0001885336 us-gaap:RelatedPartyMember 2023-05-01 2023-10-31 0001885336 us-gaap:RelatedPartyMember 2022-05-01 2022-10-31 0001885336 sesu:DirectorOfSensaSureMember 2023-10-31 0001885336 srt:DirectorMember 2022-05-01 2022-10-31 0001885336 us-gaap:RelatedPartyMember 2023-10-31 0001885336 us-gaap:RelatedPartyMember 2022-10-31 0001885336 us-gaap:RelatedPartyMember 2023-04-30 0001885336 2021-03-30 2021-03-30 0001885336 us-gaap:RelatedPartyMember sesu:RelatedPartyTransactionMember 2023-10-31 0001885336 us-gaap:RelatedPartyMember sesu:RelatedPartyTransactionMember 2023-04-30 0001885336 us-gaap:RelatedPartyMember sesu:SensaBuesABMember 2023-10-31 0001885336 us-gaap:RelatedPartyMember sesu:SensaBuesABMember 2023-04-30 0001885336 us-gaap:PreferredClassAMember 2022-10-31 0001885336 srt:MinimumMember us-gaap:PreferredClassAMember 2023-10-31 0001885336 srt:MaximumMember us-gaap:PreferredClassAMember 2023-10-31 0001885336 us-gaap:PreferredClassAMember 2022-01-31 0001885336 srt:MinimumMember us-gaap:PreferredClassBMember 2023-10-31 0001885336 srt:MaximumMember us-gaap:PreferredClassBMember 2023-10-31 0001885336 srt:BoardOfDirectorsChairmanMember us-gaap:PreferredClassBMember 2022-01-31 0001885336 2020-12-21 0001885336 2020-12-21 2020-12-21 0001885336 sesu:SensaBuesABMember 2020-05-01 2021-04-30 0001885336 sesu:SensaSureMember 2020-05-01 2021-04-30 0001885336 us-gaap:StockCompensationPlanMember 2021-05-01 2022-04-30 0001885336 us-gaap:ShareDistributionMember 2022-04-30 0001885336 2022-01-01 2022-12-31 0001885336 srt:MinimumMember 2020-05-01 2021-04-30 0001885336 srt:MaximumMember 2020-05-01 2021-04-30 0001885336 us-gaap:PreferredClassAMember us-gaap:CommonStockMember 2022-01-31 0001885336 2022-12-31 0001885336 us-gaap:PreferredClassBMember 2021-04-30 0001885336 sesu:SensaSureMember 2021-04-30 0001885336 us-gaap:PreferredClassBMember 2022-01-31 0001885336 us-gaap:PrivatePlacementMember 2023-04-30 0001885336 us-gaap:ConvertiblePreferredStockMember 2022-01-31 0001885336 2022-01-31 2022-01-31 0001885336 2022-05-01 2022-07-31 0001885336 2022-11-01 2023-01-31 0001885336 us-gaap:CommonClassBMember 2022-05-01 2023-04-30 0001885336 us-gaap:CommonClassBMember us-gaap:PreferredStockMember 2022-05-01 2023-04-30 0001885336 srt:BoardOfDirectorsChairmanMember 2022-05-01 2023-04-30 0001885336 sesu:ConsultantMember 2023-05-01 2023-10-31 0001885336 sesu:CommonSharesVestedCommonSharesIssuedMember 2021-04-30 0001885336 sesu:CommonSharesVestedCommonStockMember 2021-04-30 0001885336 sesu:CommonSharesVestedAdditionalPaidinCapitalMember 2021-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonStockMember 2021-04-30 0001885336 sesu:CommonSharesCancelledUponResignationAdditionalPaidinCapitalMember 2021-04-30 0001885336 sesu:CommonSharesOutstandingSharesMember 2021-04-30 0001885336 us-gaap:CommonStockMember 2021-04-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001885336 sesu:CommonSharesVestedCommonSharesMember 2021-05-01 2022-04-30 0001885336 sesu:CommonSharesVestedCommonStockMember 2021-05-01 2022-04-30 0001885336 sesu:CommonSharesVestedAdditionalPaidinCapitalMember 2021-05-01 2022-04-30 0001885336 sesu:CommonSharesVestedSharesMember 2021-05-01 2022-04-30 0001885336 us-gaap:CommonStockMember 2021-05-01 2022-04-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2022-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonSharesMember 2021-05-01 2022-04-30 0001885336 sesu:CommonSharesOutstandingSharesMember 2021-05-01 2022-04-30 0001885336 sesu:CommonSharesVestedCommonSharesIssuedMember 2022-04-30 0001885336 sesu:CommonSharesVestedCommonSharesMember 2022-04-30 0001885336 sesu:CommonSharesVestedCommonStockMember 2022-04-30 0001885336 sesu:CommonSharesVestedAdditionalPaidinCapitalMember 2022-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonSharesMember 2022-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonStockMember 2022-04-30 0001885336 sesu:CommonSharesCancelledUponResignationAdditionalPaidinCapitalMember 2022-04-30 0001885336 sesu:CommonSharesOutstandingSharesMember 2022-04-30 0001885336 sesu:CommonSharesVestedSharesMember 2022-04-30 0001885336 sesu:CommonSharesVestedCommonSharesMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesVestedCommonStockMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesVestedAdditionalPaidinCapitalMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonSharesMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesCancelledUponResignationAdditionalPaidinCapitalMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesVestedSharesMember 2022-05-01 2023-04-30 0001885336 us-gaap:CommonStockMember 2022-05-01 2023-04-30 0001885336 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesOutstandingSharesMember 2022-05-01 2023-04-30 0001885336 sesu:CommonSharesVestedCommonSharesIssuedMember 2023-04-30 0001885336 sesu:CommonSharesVestedCommonSharesMember 2023-04-30 0001885336 sesu:CommonSharesVestedCommonStockMember 2023-04-30 0001885336 sesu:CommonSharesVestedAdditionalPaidinCapitalMember 2023-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonSharesMember 2023-04-30 0001885336 sesu:CommonSharesCancelledUponResignationCommonStockMember 2023-04-30 0001885336 sesu:CommonSharesCancelledUponResignationAdditionalPaidinCapitalMember 2023-04-30 0001885336 sesu:CommonSharesOutstandingSharesMember 2023-04-30 0001885336 sesu:CommonSharesVestedSharesMember 2023-04-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:SEK

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

I, James Hiza, certify that:

1.	I have reviewed this Form 10-Q of SensaSure Technologies Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the unaudited condensed consolidated interim financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

[Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

Disclosed in this report is any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 18, 2023

/s/ JAMES HIZA

James Hiza

Chief Executive Officer

(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302

I, James Hiza, certify that:

1.	I have reviewed this Form 10-Q of SensaSure Technologies Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

[Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 18, 2023

/s/ JAMES HIZA

James Hiza

Acting Chief Financial Officer

(Principal Financial and Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SensaSure Technologies Inc. (the “Company”) on Form 10-Q for the quarter ended October 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I James Hiza, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 18, 2023		/s/ JAMES HIZA
	Name:	James Hiza
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 18, 2023		/s/ JAMES HIZA
	Name:	James Hiza
	Title:	Acting Chief Financial Officer
		(Principal Financial and Accounting Officer)

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Oct. 31, 2023	Dec. 15, 2023
Document Information Line Items
Entity Registrant Name	SENSASURE TECHNOLOGIES INC.
Trading Symbol	SSTC
Document Type	10-Q
Current Fiscal Year End Date	--04-30
Entity Common Stock, Shares Outstanding		56,349,183
Amendment Flag	false
Entity Central Index Key	0001885336
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Oct. 31, 2023
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-41209
Entity Tax Identification Number	87-2406468
Entity Address, Address Line One	4730 S. Fort Apache Rd.
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89147
City Area Code	(347)
Local Phone Number	325-4677
Title of 12(b) Security	Common Stock, $0.01 par value
Security Exchange Name	NONE
Entity Interactive Data Current	Yes

Condensed Interim Consolidated Balance Sheets - USD ($)	Oct. 31, 2023	Apr. 30, 2023
Current assets:
Cash	$ 3,135	$ 26,786
Restricted cash held in trust		172
Accounts receivable	788
Subscription receivable
Prepayments and other receivables	11,435	12,688
Total current assets	15,358	39,646
Total assets	15,358	39,646
Current liabilities:
Accounts payable and accrued liabilities	109,579	105,868
Accounts payable and accrued liabilities to a related party	470,445	486,826
Demand Loans	137,694	113,375
Loans from related parties	76,074	82,823
Amount due to related parties	371,736	312,347
Total current liabilities	1,165,528	1,101,239
Total liabilities	1,165,528	1,101,239
STOCKHOLDERS’ DEFICIECY
Common stock, $0.01 par value, 250,000,000 authorized as at October 31, 2023 and April 30, 2023, respectively. Issued and outstanding common shares: and 56,349,183 as at October 31, 2023 and 56,349,183 at April 30, 2023, respectively.	447,431	425,431
Shares to be issued (804,000 and 804,000 common shares at October, 2023 and April 30, 2023 respectively)	15,755	15,755
Additional paid-in capital	4,665,073	4,533,073
Foreign currency translation reserve	(170,131)	(231,505)
Accumulated deficit	(6,334,768)	(6,027,209)
Total deficit attributable to equity holders of the Company	(1,376,640)	(1,284,455)
Total equity attributable to non-controlling interests	45,669	42,061
Development reserve	180,801	180,801
Total deficit	(1,150,170)	(1,061,593)
Total liabilities and stockholders’ deficiency	15,358	39,646
Class A Preferred Stock
STOCKHOLDERS’ DEFICIECY
Preferred stock, value
Class B Preferred Stock
STOCKHOLDERS’ DEFICIECY
Preferred stock, value

Condensed Interim Consolidated Balance Sheets (Parentheticals) - $ / shares	Oct. 31, 2023	Apr. 30, 2023
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, share authorized	250,000,000	250,000,000
Common stock, share issued	56,349,183	56,349,183
Common stock, share outstanding	56,349,183	56,349,183
Common shares, issued	804,000	804,000
Class A Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, share authorized	5,000,000	5,000,000
Preferred stock, share Issued
Preferred stock, share outstanding
Class B Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, share authorized	5,000,000	5,000,000
Preferred stock, share Issued
Preferred stock, share outstanding

Condensed Interim Consolidated Statements of Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Income Statement [Abstract]
Revenue	$ 811	$ 680	$ 1,146	$ 4,414
Expenses
General and administrative expense	(154,467)	(132,641)	(296,352)	(313,909)
Research and development expense	(3,231)	(19,421)	(10,145)	(19,421)
TOTAL OPERATING EXPENSES	(157,698)	(152,062)	(306,497)	(333,330)
Interest expenses, net	(1,968)	(1,995)	(4,009)	(4,132)
Other income (expenses), net
NET LOSS BEFORE INCOME TAXES	(158,855)	(153,377)	(309,360)	(333,048)
Income taxes
NET LOSS	(158,855)	(153,377)	(309,360)	(333,048)
Less: net loss attributable to non-controlling interests	164	4,277	1,801	5,797
Net loss attributable to the Company	$ (158,691)	$ (149,100)	$ (307,559)	$ (327,251)
Basic loss per share (in Dollars per share)	$ (0.003)	$ (0.001)	$ (0.005)	$ (0.003)
Weighted average number of common shares outstanding (in Shares)	56,349,183	105,723,183	56,349,183	105,723,183

Condensed Interim Consolidated Statements of Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Income Statement [Abstract]
Diluted loss per share	$ (0.003)	$ (0.001)	$ (0.005)	$ (0.003)

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss for the period	$ (158,855)	$ (153,377)	$ (309,360)	$ (333,048)
Foreign currency translation adjustments	48,585	61,005	66,783	73,357
Total comprehensive loss for the period	(110,270)	(92,372)	(242,577)	(259,691)
Attributable to:
Net loss attributable to the Company	(158,691)	(149,100)	(307,559)	(327,251)
Foreign currency translation adjustments attributable to the Company	44,353	57,058	61,374	68,612
Net loss attributable to non-controlling interests	(164)	(4,277)	(1,801)	(5,797)
Foreign currency translation adjustments attributable to non-controlling interests	4,232	3,947	5,409	4,745
Total comprehensive loss	$ (110,270)	$ (92,372)	$ (242,577)	$ (259,691)

Condensed Interim Consolidated Statements of Stockholders’ Deficiency Equity - USD ($)	Common Stock	Shares to be issued	Additional paid-in Capital	Foreign Currency Translation Reserve	Accumulated deficit	(Deficit)	Non- controlling interests	Development Reserve	Total
Balance at Apr. 30, 2022	$ 609,351		$ 4,197,213	$ (195,610)	$ (4,433,352)	$ 177,602	$ (881,448)	$ 240,641	$ (463,205)
Balance (in Shares) at Apr. 30, 2022	105,723,183
Subsidiary issuance of shares pursuant to private placement							45		45
Amortization of vested shares	12,760		16,392			29,152			29,152
Issuance of common shares for service		$ 2,520				2,520			2,520
Issuance of common shares for service (in Shares)		36,000
Loss for the period					(327,251)	(327,251)	(5,797)		(333,048)
Foreign translation adjustment				68,612		68,612	4,745		73,357
Effect of dilution of ownership in subsidiary pursuant to issuance of shares				(51,632)	(883,768)	(935,400)	935,400
Balance at Oct. 31, 2022	$ 622,111	$ 2,520	4,213,605	(178,630)	(5,644,371)	(984,765)	52,945	240,641	(691,179)
Balance (in Shares) at Oct. 31, 2022	105,723,183	36,000
Balance at Jul. 31, 2022	$ 615,731		4,205,409	(235,688)	(5,495,271)	(909,819)	53,275	240,641	(615,903)
Balance (in Shares) at Jul. 31, 2022	105,723,183
Amortization of vested shares	$ 6,380		8,196			14,576			14,576
Issuance of common shares for service		$ 2,520				2,520			2,520
Issuance of common shares for service (in Shares)		36,000
Loss for the period					(149,100)	(149,100)	(4,277)		(153,377)
Foreign translation adjustment				57,058		57,058	3,947		61,005
Balance at Oct. 31, 2022	$ 622,111	$ 2,520	4,213,605	(178,630)	(5,644,371)	(984,765)	52,945	240,641	(691,179)
Balance (in Shares) at Oct. 31, 2022	105,723,183	36,000
Balance at Apr. 30, 2023	$ 425,431	$ 15,755	4,533,073	(231,505)	(6,027,209)	(1,284,455)	42,061	180,801	(1,061,593)
Balance (in Shares) at Apr. 30, 2023	56,349,183	804,000
Amortization of vested shares	$ 22,000		132,000			154,000			154,000
Loss for the period					(307,559)	(307,559)	(1,801)		(309,360)
Foreign translation adjustment				61,374		61,374	5,409		66,783
Balance at Oct. 31, 2023	$ 447,431	$ 15,755	4,665,073	(170,131)	(6,334,768)	(1,376,640)	45,669	180,801	(1,150,170)
Balance (in Shares) at Oct. 31, 2023	56,349,183	804,000
Balance at Jul. 30, 2023	$ 436,431	$ 15,755	4,599,073	(214,484)	(6,176,077)	(1,339,302)	41,601	180,801	(1,116,900)
Balance (in Shares) at Jul. 30, 2023	56,349,183	804,000
Amortization of vested shares	$ 11,000		66,000			77,000			77,000
Loss for the period					(158,691)	(158,691)	(164)		(158,855)
Foreign translation adjustment				44,353		44,353	4,232		48,585
Balance at Oct. 30, 2023	$ 447,431	$ 15,755	$ 4,665,073	$ (170,131)	$ (6,334,768)	$ (1,376,640)	$ 45,669	$ 180,801	$ (1,150,170)
Balance (in Shares) at Oct. 30, 2023	56,349,183	804,000

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (309,360)	$ (333,048)
Adjustments for:
Amortization of vested shares	154,000	29,152
Issuance of shares for services		2,520
Changes in:
Accounts receivable	(788)	(2,089)
Prepayments and other receivables	1,253	(1,750)
Accounts payable and accrued liabilities to third parties and a related party	(12,670)	(43,363)
Amounts due to related parties	59,389	51,544
Long term payable to a related party		(17,935)
Net cash used in operating activities	(108,176)	(314,969)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from subsidiary issuance of shares to noncontrolling interests		45
Proceeds from related party loans	70,279
Net cash provided by financing activities	70,279	45
Effect of exchange rate changes on cash and restricted cash held in trust	14,074	26,387
Net decrease in cash and restricted cash held in trust	(23,823)	(288,537)
Cash and restricted cash held in trust at the beginning of period	26,958	437,177
Cash and restricted cash held in trust at the end of period	3,135	148,640
Supplemental cash flows information
Income tax paid
Interest paid

Description of Business

6 Months Ended

Oct. 31, 2023

Description of Business [Abstract]

DESCRIPTION OF BUSINESS

1.	DESCRIPTION OF BUSINESS

Sensa Bues AB performs medical device design and research focusing on developing and commercializing EB for disease detection, exposure monitoring, and drug metabolism.

Basis of Presentation, Measurement and Consolidation

6 Months Ended

Oct. 31, 2023

Basis of Presentation, Measurement and Consolidation [Abstract]

BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

2.	BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

(a)	Basis of Presentation

(b)	Basis of Consolidation

Equity interests in Sensa Bues AB held by parties other than SensaSure are presented as non-controlling interests in equity.

(c)	Liquidity and going concern

Summary of Significant Accounting Policies

6 Months Ended

Oct. 31, 2023

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a)	Revenue recognition

The Company sells devices with collection mechanism for biological samples based upon exhaled breath. Revenue comprises devices delivered to the Company’s customers.

The principles in ASC 606 are applied using the following five steps:

Identify the contract with a customer;

Identify the performance obligation(s) in the contract;

Determine the transaction price;

Allocate the transaction price to the performance obligation(s) in the contract; and

Recognize revenue when (or as) the performance obligation(s) are satisfied.

(b)	Cash and restricted cash held in trust

(c)	Non-controlling interests

(d)	Critical management judgment and use of estimates

(e)	Accounts receivable

(f)	Research and development

Research and development and all patent maintenance and related filing costs are charged to operations as incurred as the Company is uncertain as to any future economic benefit.

(g)	Stock based compensation

(h)	Foreign Currency Translation

(i)	Fair Value of financial instruments

●

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

●

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

●

(j)	Income Taxes

(k)	Loss per share

(l)	Operating Segments

(m)	Recently issued accounting pronouncements

The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Subscription Receivable

6 Months Ended

Oct. 31, 2023

Subscription Receivable [Abstract]

SUBSCRIPTION RECEIVABLE

4.	SUBSCRIPTION RECEIVABLE

Accounts Payable and Accrued Liabilities to Third Parties

6 Months Ended

Oct. 31, 2023

Accounts Payable and Accrued Liabilities to Third Parties [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES TO THIRD PARTIES

5.	ACCOUNTS PAYABLE AND ACCRUED LIABILITIES TO THIRD PARTIES

	As of
	October 31, 2023		April 30, 2023
Accounts payable	$	46,079	$	53,868
Accrued liabilities		63,500		52,000
	$	109,579	$	105,868

Demand Loans

6 Months Ended

Oct. 31, 2023

Demand Loans [Abstract]

DEMAND LOANS

6.	DEMAND LOANS

Related Parties Transactions

6 Months Ended

Oct. 31, 2023

RELATED PARTIES TRANSACTIONS

7.	RELATED PARTIES TRANSACTIONS

The Company had the following balances and transaction with related parties except disclosed in other notes.:

(a)	Amounts due to related parties

At October 31, 2023 and April 30, 2023, expenses paid on behalf of the Company by two former directors of Sensa Bues AB included in amounts due to related parties was $nil and $ nil, respectively.

At October 31, 2023 and April 30, 2023, amounts payable to a former director of Sensa Bues AB included in amounts due to related parties was $nil and $ nil, respectively.

(b)	Loans from related parties

(c)	Payables and interest accrual to a related party

The accounts payable balance related to professional services provided by a vendor that is controlled by a then-director of Sensa Bues AB.

As at October 31, 2023, the total accounts payable and accrued liabilities to the related party was $470,445 (April 30, 2023 - $486,826).

At October 31, 2023, the current portion of the modified payable balance was $232,458 (April 30, 2023 - $240,012) and the long term portion was $nil (Aril 30, 2023 - $Nil).

Stockholders' Deficiency

6 Months Ended

Oct. 31, 2023

Stockholders' Deficiency [Abstract]

STOCKHOLDERS’ DEFICIENCY

8.	STOCKHOLDERS’ DEFICIENCY

(a)	Authorized and Issued Stock

At October 31, 2023, the Company is authorized to issue 250,000,000 (April 30, 2023 – 250,000,000) shares of common stock ($0.01 par value).

At October 31, 2023, common shares issued and outstanding totaled 56,349,183 (April 30, 2023 – 56,349,183) shares (Note 8 (b)).

At October 31, 2023, there were Nil Class A shares of Preferred Stock that were issued and outstanding (April 30, 2023 – Nil) (Note 8 (b)).

At October 31, 2023, there were Nil Class B shares of Preferred Stock that were issued and outstanding (April 30, 2023 – Nil) (Note 8 (b)).

(b)	Share issuance

Share issuance during the year ended April 30, 2021

Share issuance during the year ended April 30, 2022

Share issuance and shares to be issued during the year ended April 30, 2023

			Common shares vested						Common shares cancelled upon resignation							At year end			At year end		At year		At year end
	Common shares issued		Common shares		Common Stock		Additional paid-in Capital		Common shares			Common Stock		Additional paid-in Capital		Common shares outstanding			Common shares vested		end Common Stock		Additional paid-in Capital
	Shares		Shares		$		$		Shares			$		$		Shares			Shares		$		$
At April 30, 2021		22,000,000		-		-		-		-			-		-		22,000,000			-		-		-
Amortization of vested shares		-		3,861,000		38,610		49,600					-		-		-			3,861,000		38,610		49,600
Cancellation of common shares		-		-		-		-		(7,931,000	)		-		-		(7,931,000	)		-		-		-
At April 30, 2022		22,000,000		3,861,000		38,610		49,600		(7,931,000	)		-		-		14,069,000			3,861,000		38,610		49,600
Amortization of vested shares		-		1,621,000.00		15,950		20,490		-			-		-		-			1,621,000		15,950		20,490
Cancellation of common shares		-		0.00		0.00		0.00		(8,587,000	)		-		-		(8,587,000	)		-		-		-
At April 30, 2023		22,000,000		5,482,000		54,560		70,090		(16,518,000	)		-		-		5,482,000			5,482,000		54,560		70,090

For six months ended October 31, 2022, there were 1,276,000 number of shares vested and the Company recorded $12,760 and $16,392 into common stock and additional paid-in capital respectively.

(c)	Noncontrolling interest

	As At		As At		As At		As At
	October 31,		April 30,		October 31,		April 30,
	2023		2023		2022		2022
	(%)		(%)		(%)		(%)
Ownership percentage
Common shareholders of the Company		93.53		93.53		93.53		74.00
Noncontrolling interests		6.47		6.47		6.47		26.00

	For the quarter		For the quarter
	ended		ended
	October 31,		October 31,
	2023		2022
	$		$
Transfer from noncontrolling interests
Increase in the Company’s accumulated deficit for Sensa Bues AB issuance of common shares to the Company and noncontrolling interests (Note 8 (b))		-		(883,768	)
Change from net loss attributable to the Company and transfer from noncontrolling interests		-		(883,768	)

(d)	Development reserve

Contingency

6 Months Ended

Oct. 31, 2023

Contingency [Abstract]

CONTINGENCY

9.	CONTINGENCY

Subsequent Events

6 Months Ended

Oct. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

10.

SUBSEQUENT EVENTS

Accounting Policies, by Policy (Policies)

6 Months Ended

Oct. 31, 2023

Summary of Significant Accounting Policies [Abstract]

Revenue Recognition

(a)	Revenue recognition

The Company sells devices with collection mechanism for biological samples based upon exhaled breath. Revenue comprises devices delivered to the Company’s customers.

The principles in ASC 606 are applied using the following five steps:

Identify the contract with a customer;

Identify the performance obligation(s) in the contract;

Determine the transaction price;

Allocate the transaction price to the performance obligation(s) in the contract; and

Recognize revenue when (or as) the performance obligation(s) are satisfied.

Cash and restricted cash held in trust

(b)	Cash and restricted cash held in trust

Non-controlling interests

(c)	Non-controlling interests

Critical management judgment and use of estimates

(d)	Critical management judgment and use of estimates

Accounts receivable

(e)	Accounts receivable

Research and development

(f)	Research and development

Research and development and all patent maintenance and related filing costs are charged to operations as incurred as the Company is uncertain as to any future economic benefit.

Stock based compensation

(g)	Stock based compensation

Foreign Currency Translation

(h)	Foreign Currency Translation

Fair Value of financial instruments

(i)	Fair Value of financial instruments

●

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

●

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

●

Income Taxes

(j)	Income Taxes

Loss per share

(k)	Loss per share

Operating Segments

(l)	Operating Segments

Recently issued accounting pronouncements

(m)	Recently issued accounting pronouncements

The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Accounts Payable and Accrued Liabilities to Third Parties (Tables)

6 Months Ended

Oct. 31, 2023

Accounts Payable and Accrued Liabilities to Third Parties [Abstract]

Schedule of Accounts Payable and Accrued Liabilities to Third Parties

	As of
	October 31, 2023		April 30, 2023
Accounts payable	$	46,079	$	53,868
Accrued liabilities		63,500		52,000
	$	109,579	$	105,868

Stockholders' Deficiency (Tables)

6 Months Ended

Oct. 31, 2023

Stockholders' Deficiency [Abstract]

Schedule of Share Issuance and Shares to Be Issued Stockholders equity

Those common shares issued were subject to a 60 months service period. The detailed accounting treatment for those issued but unvested shares are as below:

			Common shares vested						Common shares cancelled upon resignation							At year end			At year end		At year		At year end
	Common shares issued		Common shares		Common Stock		Additional paid-in Capital		Common shares			Common Stock		Additional paid-in Capital		Common shares outstanding			Common shares vested		end Common Stock		Additional paid-in Capital
	Shares		Shares		$		$		Shares			$		$		Shares			Shares		$		$
At April 30, 2021		22,000,000		-		-		-		-			-		-		22,000,000			-		-		-
Amortization of vested shares		-		3,861,000		38,610		49,600					-		-		-			3,861,000		38,610		49,600
Cancellation of common shares		-		-		-		-		(7,931,000	)		-		-		(7,931,000	)		-		-		-
At April 30, 2022		22,000,000		3,861,000		38,610		49,600		(7,931,000	)		-		-		14,069,000			3,861,000		38,610		49,600
Amortization of vested shares		-		1,621,000.00		15,950		20,490		-			-		-		-			1,621,000		15,950		20,490
Cancellation of common shares		-		0.00		0.00		0.00		(8,587,000	)		-		-		(8,587,000	)		-		-		-
At April 30, 2023		22,000,000		5,482,000		54,560		70,090		(16,518,000	)		-		-		5,482,000			5,482,000		54,560		70,090

Schedule of Ownership Interests and Noncontrolling Interests

	As At		As At		As At		As At
	October 31,		April 30,		October 31,		April 30,
	2023		2023		2022		2022
	(%)		(%)		(%)		(%)
Ownership percentage
Common shareholders of the Company		93.53		93.53		93.53		74.00
Noncontrolling interests		6.47		6.47		6.47		26.00

Schedule of Share Issuance and Shares to Be Issued

	For the quarter		For the quarter
	ended		ended
	October 31,		October 31,
	2023		2022
	$		$
Transfer from noncontrolling interests
Increase in the Company’s accumulated deficit for Sensa Bues AB issuance of common shares to the Company and noncontrolling interests (Note 8 (b))		-		(883,768	)
Change from net loss attributable to the Company and transfer from noncontrolling interests		-		(883,768	)

Description of Business (Details) - shares			1 Months Ended	6 Months Ended
Description of Business (Details) - shares	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021	Oct. 31, 2023	Oct. 31, 2022	Sep. 08, 2020
Description of Business [Line Items]
Authorized share capital	250,000,000			250,000,000
Description of share exchange agreement				the Company completed a reverse recapitalization via a share exchange agreement with Sensa Bues AB and the shareholders who owned 270,339 common shares that represented 72.82% of the total issued and outstanding common shares in Sensa Bues AB. Under the share exchange agreement, the shareholders of Sensa Bues AB, agreed to exchange their shares of Sensa Bues AB for common shares of SensaSure at an exchange ratio of approximate 1:49.99. Pursuant to the share exchange transactions (see share exchange agreement noted above), SensaSure issued a total of 13,515,183 common shares and the then-shareholders of Sensa Bues AB hold their ownership of Sensa Bues AB through SensaSure (Note 8 (b)). Upon completion of the share exchange transaction, SensaSure became the controlling shareholder that owned 74.82% the total issued and outstanding common shares in Sensa Bues AB and parent company of Sensa Bues AB (“Subsidiary”).
Common share issued					2,200,000
Common shares noncontrolling interests					440
Private Placement [Member]
Description of Business [Line Items]
Common share issued			277,296
Common shares noncontrolling interests			93,032
Common Stock [Member]
Description of Business [Line Items]
Percentage of common shares outstanding	93.53%	74.00%		93.53%	93.53%
SensaSure Technologies, Inc. [Member]
Description of Business [Line Items]
Authorized share capital						250,000,000
SensaSure Technologies, Inc. [Member] \| Class A Preferred shares
Description of Business [Line Items]
Preferred shares authorized						5,000,000
SensaSure Technologies, Inc. [Member] \| Class B Preferred shares
Description of Business [Line Items]
Preferred shares authorized						5,000,000

Basis of Presentation, Measurement and Consolidation (Details) - USD ($)	Oct. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021	Mar. 30, 2021
Basis of Presentation, Measurement and Consolidation [Line Items]
Accumulated deficit	$ (6,334,768)	$ (6,027,209)
Working capital deficiency	1,150,170	1,061,593
Private placements			$ 368,200	$ 893,014
Working capital loans from related parties		39,979
Payable balance					$ 333,744
Liquidity and Going Concern [Member]
Basis of Presentation, Measurement and Consolidation [Line Items]
Accumulated deficit	$ (6,334,768)	$ (6,027,209)

Summary of Significant Accounting Policies (Details)	6 Months Ended
Summary of Significant Accounting Policies (Details)	Oct. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Tax benefit settlement percentage	50.00%

Subscription Receivable (Details) - USD ($)	6 Months Ended	12 Months Ended
Subscription Receivable (Details) - USD ($)	Oct. 31, 2023	Apr. 30, 2022	Apr. 30, 2021
Subscription Receivable [Abstract]
Proceeds, net			$ 793,000
Common shares subscribed			12,200,000
Issued of common shares			11,780,000
Proceeds received amount	$ 117,800
Additional paid-in capital in amount	$ 647,900
Subscription receivable amount			$ 27,300
Number of shares issued	420,000
Subscription proceeds received from common shares issued		420,000

Accounts Payable and Accrued Liabilities to Third Parties (Details) - Schedule of Accounts Payable and Accrued Liabilities to Third Parties - USD ($)	Oct. 31, 2023	Apr. 30, 2023
Schedule of Accounts Payable and Accrued Liabilities to Third Parties [Abstract]
Accounts payable	$ 46,079	$ 53,868
Accrued liabilities	63,500	52,000
Total	$ 109,579	$ 105,868

Demand Loans (Details)	6 Months Ended
Demand Loans (Details)	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2023 SEK (kr)	Apr. 30, 2023 USD ($)	Apr. 30, 2023 SEK (kr)
Demand Loans [Line Items]
Several noncontrolling interests	$ 26,223		kr 293,000	$ 28,550	kr 293,000
Interest rate	20.00%		20.00%
Interest expense	$ 2,719	$ 2,802
Balance in demand loan	70,279			39,979
Sensa Bues AB [Member]
Demand Loans [Line Items]
Several noncontrolling interests	$ 41,192		kr 460,247	$ 44,846	kr 460,247
Interest rate	2.00%		2.00%
Interest expense	$ 427	$ 440

Related Parties Transactions (Details)				3 Months Ended		6 Months Ended		12 Months Ended
Related Parties Transactions (Details)	Mar. 31, 2021 USD ($) shares	Mar. 30, 2021 USD ($)	Mar. 30, 2021 SEK (kr)	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Apr. 30, 2023 USD ($)	Oct. 31, 2023 SEK (kr)	Apr. 30, 2023 SEK (kr)
Related Parties Transactions [Line Items]
Amounts due to related parties
Account payable				$ 46,079		46,079		53,868
Aggregated common shares (in Shares) \| shares	3,400
Number of common shares (in Shares) \| shares	50
Due to related parties expense
Loans from a former director				26,850		$ 26,850		29,232	kr 550,000	kr 300,000
Unsecured bearing interest						2.00%
Interest expense				1,968	$ 1,995	$ 4,009	$ 4,132
Accounts payable and accrued liabilities				470,445		470,445
Research and development				3,231	19,421	10,145	19,421
Professional services		$ 333,744	kr 798,280
Long term portion
Director [Member]
Related Parties Transactions [Line Items]
Loans from a former director				49,224		$ 49,224		53,591		kr 550,000
Unsecured bearing interest						2.00%
Interest expense						$ 278	319
Sensa Bues AB [Member] \| CEO [Member]
Related Parties Transactions [Line Items]
Amounts due to related parties						371,736		312,347
Related Party [Member]
Related Parties Transactions [Line Items]
Account payable	$ 326,337							486,826
Interest expense						510	568
Accrued liabilities				138,483	$ 138,483	138,483	$ 138,483
Related Party [Member] \| Related Party Transaction [Member]
Related Parties Transactions [Line Items]
Account payable				6,701		6,701		6,701
Related Party [Member] \| Sensa Bues AB [Member]
Related Parties Transactions [Line Items]
Account payable				$ 232,458		$ 232,458		$ 240,012
Director of Sensa Sure [Member]
Related Parties Transactions [Line Items]
Loans from a former director \| kr									kr 300,000

Stockholders' Deficiency (Details) - USD ($)			3 Months Ended		6 Months Ended		12 Months Ended
Stockholders' Deficiency (Details) - USD ($)	Jan. 31, 2022	Dec. 21, 2020	Jan. 31, 2023	Jul. 31, 2022	Oct. 31, 2023	Oct. 31, 2022	Apr. 30, 2023	Dec. 31, 2022	Apr. 30, 2022	Apr. 30, 2021
Stockholders Deficiency [Line Items]
Common stock, shares authorized					250,000,000		250,000,000
Common stock, par value (in Dollars per share)					$ 0.01		$ 0.01
Conversion rate of common shares								21,637,000
Common stock, shares issued					56,349,183		56,349,183
Common stock, shares outstanding					56,349,183		56,349,183
Private placement for proceeds (in Dollars)										$ 99,643
Issued common shares										10,000
Issuance of shares of common stock										499,935
Proceeds received (in Dollars)					$ 4,999
Additional paid-in capital amount (in Dollars)					$ 94,644	$ 16,392
Owned common shares		270,339
Owned common shares percentage		72.82%
Issued common shares		13,515,183								11,780,000
Share exchange agreement ,description					Shareholders agreed that from the Effective Date of share exchange agreement the Shareholders shall have up to 243,402 shares to sell when a trading market begins on the OTC Markets. Eighteen (18) months after the initial listing date of the shares on the NASDAQ Market, the Shareholder shall have 1,914,704 shares available to sell. Twenty-four (24) months after the initial listing date of the shares on the NASDAQ Market, the Shareholders shall have 5,744,109 shares available to sell.
Private placements for proceeds (in Dollars)										$ 793,000
Restricted common shares										12,200,000
Agreement ,description					The proceeds received was reflected as an increase in common stock in amount of $117,800 and additional paid-in capital in amount of $647,900 respectively. The Company recognized a subscription receivable in amount of $27,300 as well as shares to be issued at April 30, 2021. The number of shares to be issued was 420,000. The Company received the subscription proceeds subsequently to year end and issued 420,000 common shares accordingly (Note 4). The subscribers entered into lock up agreement pursuant to which (1) The Shareholders shall 1,715,800 of the shares subscribed to sell when a trading market begins on the OTC Markets; (ii) The Shareholders shall have 5,346,000 of their remaining shares available to sell Six (6) months after the initial listing date of the shares on the NASDAQ Market; (iii) The Shareholders shall have their remaining shares for trading Eighteen (18) months after the initial listing date of the shares on the NASDAQ Market; and (iv) In the event the stock does not begin trading on the NASDAQ Market within a period of Thirty-Six (36) months after the execution of the Share Exchange Agreement, the Shareholders shall have up to Thirty Percent (30%) of their remaining shares available to sell after the initial listing date of the shares on the OTC Market. The balance of the Shareholder’s shares shall be available for trading Sixty (60) months after the initial listing date of the shares on the OTC Market (the “Lock Up Period”).				The proceeds received was reflected as an increase in common stock in amount of $48,700 and additional paid-in capital in amount of $292,200 respectively. The subscribers entered into lock up agreement and the shareholders shall have 502,584 shares available to sell upon a trading market begins on OTC Market, 356,484 shares available to sell upon six months after a trading market begins on OTC Market, 218,663 shares available to sell upon initial listing date on the Nasdaq Market, 289,278 shares available to sell upon six months after initial listing date on the Nasdaq Market, 37,012 shares available to sell upon twelve months after initial listing date on the Nasdaq Market, 176,781 shares available to sell upon eighteen months after the initial listing date on Nasdaq Market, 304,862 shares available to sell upon twenty four months after the initial listing date on Nasdaq Market and the balance of the shareholders’ shares will be available to sell upon sixty months after the initial listing date on Nasdaq Market.
Shares available, description					After the revision, the shareholders shall have 10,898,736 shares available to sell upon a trading market begins on OTC Market, 7,738,000 shares available to sell upon six months after a trading market begins on OTC Market, 4,750,000 shares available to sell upon initial listing date on the Nasdaq Market, 6,280,000 shares available to sell upon six months after initial listing date on the Nasdaq Market, 800,000 shares available to sell upon twelve months after initial listing date on the Nasdaq Market, 3,838,213 shares available to sell upon eighteen months after the initial listing date on Nasdaq Market, 6,620,863 shares available to sell upon twenty four months after the initial listing date on Nasdaq Market and the balance of the shareholders’ shares will be available to sell upon sixty months after the initial listing date on Nasdaq Market.
Fair value of the shares issued (in Dollars)					$ 502,614
Unvested shares								8,587,000	7,931,000
General and administrative expenses (in Dollars)					36,440
General and administrative expenses (in Dollars)					15,950
Common stock (in Dollars)					$ 20,490	$ 12,760
Preferred stock issued to directors										24,371
Fair value of the share-based compensation (in Dollars)							$ 16,500			$ 360,795
Transferred to additional paid in capital (in Dollars)									$ 216,370
Cancellation of common shares								27,950,000
Fair value of options issued (in Dollars)
Common shares					50
Subscription receivable amount (in Dollars)										$ 27,300
Number of shares issued					420,000
Proceeds received from common stock issued									420,000
Several private placements (in Dollars)									$ 340,900
Per share (in Dollars per share)									$ 0.07
Issuance of common stock description					During the year ended April 30, 2022, the Company approved the issuance of 2,118,000 shares of the common stock to several consultants and directors. The fair value of the share-based compensation was in the amount of $148,260 and was included in the general and admirative expenses as well as a credit made in common stock in amount of 21,180 and additional paid-in capital in amount of 127,080 respectively. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. One of the consultants is a related party individual and the share awards was 2,100,000 common shares with an amount of 147,000.During the year ended April 30, 2022, SensaSure issued 3,080,000 common stock to a consultant of the Company for services to be provided in future including completion of certain financing projects and regulatory services. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. At April 30, 2022 and 2023, none of these services were rendered. Accordingly, the Company has not recognized any share based compensation expense during the year.
Share issued							54,000
Share based compensation (in Dollars)							$ 3,780
Price Per share (in Dollars per share)							$ 0.07
Common shares issued for services							750,000
Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance							750,000
Share based compensation (in Dollars)	$ 11,975						$ 115,500
Common share				2,200,000
Cash consideration (in Dollars)				$ 225,641
Issuance of shares of common stock			8,800,000
Common shares vested						1,276,000	1,650,000
Shares issued										22,000,000
Unvested common shares					4,950,000		3,080,000
Common stock value issued (in Dollars)							$ 35,500
Unvested shares amount (in Dollars)					$ 49,500
Accumulated deficit (in Dollars)							59,804		$ 108,102
Share Issuance [Member]
Stockholders Deficiency [Line Items]
Additional paid-in capital amount (in Dollars)									49,600
Common stock in amount (in Dollars)									$ 38,610
Common Stock [Member]
Stockholders Deficiency [Line Items]
Additional paid-in capital amount (in Dollars)					132,000
Common stock in amount (in Dollars)							$ 99,000
Common stock (in Dollars)					$ 22,000
Proceeds received from common stock issued									4,870,000
Minimum [Member]
Stockholders Deficiency [Line Items]
General and administrative expenses (in Dollars)										$ 24
Maximum [Member]
Stockholders Deficiency [Line Items]
General and administrative expenses (in Dollars)										$ 360,771
Class B Preferred Stock [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares	31,500,000
Preferred stock shares issued										31,500
Private Placement [Member]
Stockholders Deficiency [Line Items]
Price Per share (in Dollars per share)							$ 0.07
Convertible Preferred Stock [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares	31,500,000
SensaSure [Member]
Stockholders Deficiency [Line Items]
Issued common shares										22,000,000
Class A Preferred Stock [Member]
Stockholders Deficiency [Line Items]
Preferred stock, shares authorized					5,000,000	5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)					$ 0.001	$ 0.001	$ 0.001
Conversion rate of common shares	24,371,000
Common share, voting rights					1,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Preferred Stock [Member] \| Common Stock [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares	24,371,000
Class A Preferred Stock [Member] \| Minimum [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares					1
Class A Preferred Stock [Member] \| Maximum [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares					1,000
Class B Preferred Stock [Member]
Stockholders Deficiency [Line Items]
Preferred stock, shares authorized					5,000,000		5,000,000
Preferred stock, par value (in Dollars per share)					$ 0.001		$ 0.001
Common share, voting rights					1,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class B Preferred Stock [Member] \| Minimum [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares					1
Class B Preferred Stock [Member] \| Maximum [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares					1,000
Common Stock [Member]
Stockholders Deficiency [Line Items]
Common shares vested					2,200,000
Class B Common Stock [Member]
Stockholders Deficiency [Line Items]
Unvested common shares							2,800,000
Class B Common Stock [Member] \| Preferred Stock [Member]
Stockholders Deficiency [Line Items]
Common shares vested							750,000
Director [Member] \| Class B Preferred Stock [Member]
Stockholders Deficiency [Line Items]
Conversion rate of common shares	31,500,000
Share-Based Payment Arrangement [Member]
Stockholders Deficiency [Line Items]
General and administrative expenses (in Dollars)									$ 88,210
Sensa Bues AB [Member]
Stockholders Deficiency [Line Items]
Issued common shares										267,296
Private placements for proceeds (in Dollars)										$ 27,671
Common shares to noncontrolling interest										93,032
Noncontrolling interest (in Dollars)										$ 27,671
Cash consideration (in Dollars)										80,800
Accounts payable (in Dollars)										326,337
SensaSure [Member]
Stockholders Deficiency [Line Items]
Fair value of the shares issued (in Dollars)										$ 502,952
Director [Member]
Stockholders Deficiency [Line Items]
Unvested common shares							7,150,000
Unvested shares amount (in Dollars)							$ 71,500
Consultant [Member]
Stockholders Deficiency [Line Items]
Unvested common shares					3,080,000
Unvested shares amount (in Dollars)					$ 30,800

Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Common shares vested Common shares issued [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance (in Shares)	22,000,000	22,000,000
Balance (in Shares)	22,000,000	22,000,000
Common shares vested Common Stock [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance	$ 38,610
Amortization of vested shares	15,950	38,610
Cancellation of common shares	0
Balance	54,560	38,610
Common shares vested Additional paid-in Capital [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance	49,600
Amortization of vested shares	20,490	49,600
Cancellation of common shares	0
Balance	70,090	49,600
Common shares cancelled upon resignation Common Stock [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance
Balance
Common shares cancelled upon resignation Additional paid-in Capital [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance
Amortization of vested shares
Balance
Common Shares Outstanding Shares [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance (in Shares)	14,069,000	22,000,000
Cancellation of common shares (in Shares)	(8,587,000)	(7,931,000)
Balance (in Shares)	5,482,000	14,069,000
Common Stock [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance	$ 38,610
Amortization of vested shares	15,950	38,610
Balance	54,560	38,610
Additional Paid-in Capital [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance	49,600
Amortization of vested shares	20,490	49,600
Balance	$ 70,090	$ 49,600
Common shares vested Common shares [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance (in Shares)	3,861,000
Amortization of vested shares (in Shares)	1,621,000	3,861,000
Cancellation of common shares (in Shares)	0
Balance (in Shares)	5,482,000	3,861,000
Common Shares Vested Shares [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance (in Shares)	3,861,000
Amortization of vested shares (in Shares)	1,621,000	3,861,000
Balance (in Shares)	5,482,000	3,861,000
Common Shares Cancelled Upon Resignation Common shares [Member]
Stockholders' Deficiency (Details) - Schedule of Share Issuance and Shares to Be Issued Stockholders equity [Line Items]
Balance (in Shares)	(7,931,000)
Amortization of vested shares (in Shares)
Cancellation of common shares (in Shares)	(8,587,000)	(7,931,000)
Balance (in Shares)	(16,518,000)	(7,931,000)

Stockholders' Deficiency (Details) - Schedule of Ownership Interests and Noncontrolling Interests	Oct. 31, 2023	Apr. 30, 2023	Oct. 31, 2022	Apr. 30, 2022
Ownership percentage
Common shareholders of the Company	93.53%	93.53%	93.53%	74.00%
Noncontrolling interests	6.47%	6.47%	6.47%	26.00%

Stockholders' Deficiency (Details) - Schedule of Transfer from Noncontrolling Interests - USD ($)	6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Schedule of Transfer from Noncontrolling Interests [Abstract]
Transfer from noncontrolling interests
Increase in the Company’s accumulated deficit for Sensa Bues AB issuance of common shares to the Company and noncontrolling interests (Note 8 (b))		(883,768)
Change from net loss attributable to the Company and transfer from noncontrolling interests		$ (883,768)